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1 Summary 
Neisseria meningitidis, a commensal β-proteobacterium 
residing exclusively in the human nasopharynx, is a 
leading cause of sepsis and epidemic meningitis 
worldwide. While comparative genome analysis was able 
to define hyperinvasive lineages that are responsible for 
most of the cases of invasive meningococcal disease 
(IMD), the genetic basis of their virulence remains 
unclear. Recent studies demonstrate that the type II-C 
CRISPR/Cas system of meningococci is associated with 
carriage and less invasive lineages. CRISPR/Cas, an 
adaptive defence system against foreign DNA, was 
shown to be involved in gene regulation in 
Francisella novicida. This study shows that knockout 
strains of N. meningitidis lacking the Cas9 protein are 
impaired in the adhesion to human nasopharyngeal cells 
in a strain-dependant manner, which constitutes a 
central step in the pathogenesis of IMD. Consequently, 
this study indicates that the meningococcal CRISPR/Cas 
system fulfils functions beyond the defence of foreign 
DNA and is involved in the regulation of meningococcal 
virulence. 
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2 Zusammenfassung 
Neisseria meningitidis, ein ß-Proteobakterium, welches 
als Kommensale ausschließlich den humanen 
Nasopharynx besiedelt, ist ein weltweit führender 
Verursacher von Sepsis und epidemischer Meningitis. 
Auch wenn mittels vergleichender Genomanalysen 
hyperinvasive Stämme definiert werden konnten, welche 
für die meisten Fälle von invasiven 
Meningokokkenerkrankungen verantwortlich sind, bleibt 
die genetische Grundlage ihrer Virulenz ungeklärt. In 
vorangegangenen Studien konnte gezeigt werden, dass 
das Typ II-C CRISPR/Cas-System der Meningokokken 
assoziiert ist mit Trägerstämmen. CRISPR/Cas ist ein 
adaptives Verteidigungssystem der Bakterien gegen 
fremde DNA, das darüber hinaus Aufgaben in der 
Genregulation von Francisella novicida erfüllt. Diese 
Arbeit zeigt, dass knockout Stämme von N. meningitidis, 
denen das Cas9-Protein fehlt, in Abhängigkeit von ihrem 
genetischen Hintergrund die Fähigkeit verlieren an 
Zellen des menschlichen Nasopharynx zu adhärieren. 
Die Adhäsion an den Wirtszellen stellt einen zentralen 
Schritt in der Pathogenese der invasiven 
Meningokokkenerkrankungen dar. Die Ergebnisse dieser 
Zusammenfassung 
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Arbeit deuten darauf hin, dass das CRISPR/Cas-System 
in Meningokokken neben seiner Funktion als bakterielles 
Immunsystem an der Regulation der bakteriellen 
Virulenz beteiligt sein könnte. 
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3 Introduction 
3.1 Neisseria meningitidis - an accidental 
pathogen 
N. meningitidis is an encapsulated, aerobic, gram-
negative diplococcus that resides predominantly on 
mucosal surfaces of the upper respiratory tract in 
humans [1]. This genetically highly diverse 
β-proteobacterium is part of the family of Neisseriaceae 
and shares about 90% nucleotide identity with 
N. lactamica and N. gonorrhoeae [1]. While 
N. meningitidis can be found in the nasopharynx of up to 
10% of the healthy population as a commensal 
bacterium [2], it sometimes leads to severe infections 
such as sepsis, purulent meningitis, or Waterhouse-
Friderichsen-syndrome, which are lethal in 10% of the 
cases and occur as sporadic cases and as global 
epidemics [3, 4].  
The only natural habitat of N. meningitidis is the human 
nasopharynx and therefore the colonisation without 
sequelae is eminently important for the transmission via 
inhalation of airborne droplets or close contact [5, 6]. 
Crucial for colonization is the adhesion of the bacteria to 
the epithelial cell layer in the human nasopharynx [7]. 
Introduction 
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Meningococci can sometimes, probably by accident, 
cross the mucosal surface of the nasopharynx and enter 
the bloodstream [8]. In this nutrient rich environment, the 
bacteria multiply rapidly, evade the immune system of 
the host, and cause life-threatening sepsis [9]. Once they 
reach the endothelial cell layer of brain vessels, they 
may cross the blood-brain barrier and replicate in the 
human cerebrospinal fluid of the subarachnoidal space, 
which causes acute bacterial meningitis [1, 7]. The 
mechanisms that drive these commensal bacteria to 
cause invasive disease remain enigmatic [10]. Invasive 
meningococcal disease (IMD) regularly fails to promote 
the spread of bacteria between patients and frequently 
kills the host, and this therefore signifies an evolutionary 
dead end for the invasive bacteria [8].  
3.2 Pathogenomics of N. meningitidis 
In contrast to pathogenic Escherichia coli, a defined set 
of virulence genes remains untraceable in 
N. meningitidis [11]. With regard to the genetic 
equipment, meningococcal strains isolated from healthy 
carriers and patients suffering from IMD are almost 
indistinguishable [12]. Numerous factors have been 
described that are involved in the bacteria-host 
interaction and thus might coincidentally contribute to 
Introduction 
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meningococcal virulence: the polysaccharide capsule 
[13], various adhesins [14], endotoxins such as 
lipopolysaccharides [15], and its natural competence for 
the uptake of DNA that leads to a high genome flexibility 
[16]. However, many of the so-called meningococcal 
virulence genes have also been found in commensal 
strains [17]. Nevertheless, analysis of meningococcal 
isolates by multilocus sequence typing revealed the 
presence of hyperinvasive lineages responsible for most 
IMD cases [18]. The genetic basis of virulence in these 
strains remains unclear. It has been shown that 
clustered, regularly interspaced, short palindromic 
repeats (CRISPR), and CRISPR-associated (cas) genes 
are more frequently found in non-hyperinvasive strains 
[19] and thus might constitute an ‘anti-virulence’ factor in 
meningococci. 
3.3 CRISPR/Cas 
The CRISPR/Cas system is a sequence based, adaptive 
bacterial defence system against viruses and invading 
DNA [20]. It is characterized by the CRISPR array, a 
sequence of noncoding DNA that contains palindromic 
repeats which are almost always identical within a 
particular array [21]. Those repeats are separated by 
unique parts of DNA, called spacers, which were found 
Introduction 
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to match frequently to phages and other 
extrachromosomal elements [22-26]. The CRISPR/Cas 
system additionally contains a set of two to six cas 
genes with functional domains, including endo- and 
exonuclease domains, helicases, RNA-DNA binding 
domains, and domains involved in transcription 
regulation [21, 22, 27, 28]. The CRISPR/Cas system 
may be found in various prokaryotic organisms and is 
therefore manifold. Between species, the repeat and the 
spacer sequences may differ in number, length, and 
structure [21, 29, 30] as well as the total number of 
CRISPR/Cas loci in the genome [31] or the number and 
sequence of the Cas genes [22]. The CRISPR/Cas 
systems may be divided into six main types 
distinguished by their Cas genes [32]. One of these, the 
type II CRSIPR/Cas systems is associated with 
pathogenic bacteria such as F. novicida, 
Campylobacter jejuni, and N. meningitidis [33]. This type 
of CRISPR/Cas system, which is only found in a bacteria 
[33], yields cas genes encoding for Cas1, Cas2, and, 
demarcating from other groups, Cas9 [34]. The group is 
further divided into three subgroups according to the 
presence or absence of a fourth protein. Type II-A 
Introduction 
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obtains additionally a gene called csn2, type II-B cas4, 
whereas type II-C lacks a fourth cas gene [35]. 
The role of the Type II CRISPR/Cas systems in host 
protection is well established [36]. CRISPR RNA 
(crRNA), processed by the endogenous endonuclease 
RNase III (encoded by rnc) [37] and a trans activating 
CRISPR RNA (tracrRNA), build a ribonucleoprotein 
complex with Cas9 to recognize target DNA by 
sequence and degrade it by cleavage [38, 39].  
However, far less is known about the potential 
contribution of the CRISPR/Cas system to gene 
regulation and virulence [40, 41]. A recent study 
revealed that Cas9 is critical for the interaction of 
C. jejuni with host cells [42]. Furthermore, it has been 
demonstrated that Cas9 in combination with tracrRNA 
and a small CRISPR/Cas-associated RNA (scaRNA) is 
involved in gene regulation in F. novicida. The 
ribonucleoprotein complex degrades the mRNA of a 
bacterial lipoprotein (blp) called FTN_1102 and therefore 
downregulates the respective gene. Furthermore, it has 
been shown that in F. novicida, the crRNA, Cas1, Cas2, 
Cas4, and the endogenous RNase III are not involved in 
this pathway [35]. Nevertheless, the authors of the study 
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analysed virulence traits of cas9 deletion mutants in 
N. meningitidis strain 92045. Since the mutants were 
unable to adhere to, invade, and replicate in human 
adenocarcinoma alveolar basal epithelial cells, a 
contribution of Cas9 to pathogenicity and virulence of 
meningococci has been assumed. However, pneumonia 
is rarely a part of IMD [43] and the CRISPR/Cas systems 
of F. novicida and N. meningitidis are similar but not 
identical, and therefore the results are not necessarily 
applicable.  
Cas4 is present in F. novicida but absent in 
N. meningitidis, which is why the meningococcal 
CRISPR/Cas system is classified as type II-C whereas 
F. novicida harbours a type II-B CRISPR/Cas system 
[34, 44]. Nevertheless, the meningococcal CRISPR/Cas 
system, which has recently been described as the most 
streamlined CRISPR/Cas system characterized to date, 
uses a unique rnc-independent crRNA maturation 
pathway with promoters within each CRISPR repeat. 
Furthermore, it is in possession of two forms of tracrRNA 
differing in length processed by RNase III [32, 45].  
An obvious explanation for the association of 
CRISPR/Cas to non-hyperinvasive strains is the 
Introduction 
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restriction of lysogenization with the meningococcal 
disease-associated prophage MDA, which was shown 
to increase host cell colonization [46]. While there was a 
highly significant inverse association between the 
presence of a CRISPR/Cas locus and MDAΦ [19], 
isolates such as the N. meningitidis serogroup C strain 
8013 and the serogroup A strain WUE2594 belong to 
hyperinvasive lineages, which contain a CRISPR/Cas 
system but lack MDA [47, 48]. Therefore, these strains 
are particularly suitable to examine the putative 
regulatory function of the CRISPR/Cas system on genes 
mediating meningococcal virulence. 
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Table 3.1 Comparison of the two meningococcal strains 
used in this study 
 8013 WUE2594 
Genome characteristics 
GenBank accession number FM999788 FR774048 
Genome size (Mb) 2.28 2.23 
GC content 51.4% 51.8% 
Predicted number of coding 
sequences 
1912 1941 
Molecular epidemiology 
Lineage Invasive Invasive 
Source IMD IMD 
Country France Germany 
Year of isolation 1989 1991 
Clonal complex (CC) ST-18 ST-5 
Serogroup C A 
Reference [47] [48] 
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3.4 The genetic basis for the interaction of 
N. meningitidis with human host cells 
The adhesion of meningococci to host cells is a process 
actively promoted by the bacteria, and their capacity to 
adhere depends on their genetic equipment. It is mainly 
affected by the type IV pilus (tfp), the so-called major 
adhesins Opa and Opc, minor adhesins such as NhhA, 
App or NadA and the polysaccharide capsule 
[14, 49, 50].  
In almost all aspects of meningococcal colonization and 
infection, tfp plays a central role. [51] They are 
homopolymeric filaments composed of the major subunit 
pilin (pilE) but many more genes are required for tfp 
biogenesis and/or function [47, 52].  
Neisserial tfp is divided into two classes based on the 
binding of the monoclonal antibody SM1 to pilin [53]. 
Class I pilin contains the conserved amino acid motif 
EYYLN recognized by SM1 and is encoded by a pilE 
gene that is located in the genome between the genes 
fkbP and lpxC [54, 55]. In close proximity to the PilE 
gene, the class I locus contains pilS (silent) cassettes. 
These are not expressed but occasionally recombine 
with pilE, hence promoting variety of possible pilin 
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versions. This process is called antigenic variation and 
requires a conserved motif called guanine quartets (G4) 
adjacent to pilE [56]. It is furthermore enhanced by a 
66 bp long sequence named Sma/Cla element [57]. 
However, in meningococci expressing class II pili, pilE 
and pilS are found in distinct loci. In addition, the pilS 
cassettes are less numerous and the G4 and Sma/Cla 
elements are absent in the pilE locus. There is evidence 
that class II tfp do not undergo antigenic variation. Strain 
8013 is known to harbour a class I tfp whereas 
WUE2594 possesses a class II pilin [55]. The pilE loci of 
8013 and WUE2594 are depicted in Figure 3.1.  
Introduction 
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Figure 3.1 pilE and pilS loci in 8013 and WUE2594 
Depicted are the pilE and pilS loci of N. meningitidis 
8013 (A) and WUE2594 (B). The scalebar in each panel 
in bp above the genes denotes the place in the genome 
according to the published genome sequence. Black 
vertical lines indicate guanine quartets (G4, 
5′-GGGTGGGTTGGGTGGG-3′) and black boxes 
Sma/Cla sequences [55]. Drawn to scale. 
 
In general, pilin is synthesized as prepilin and 
subsequently cleaved by the prepilin peptidase pilD [58]. 
After processing, the mature pilin is approximately 
145-160 aa long with 25 conserved hydrophobic 
N-terminal residues that are embedded in the core of the 
pilus and a C-terminal disulphide bond, which is partially 
exposed at the surface. The posttranslational 
modifications of pilin include the glycosylation of serine 
residues, controlled by the pgl gene cluster [59-62]. 
Several other proteins are necessary for tfp function. 
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PilG is known to be required for piliation [63]. PilF 
promotes the elongation [64] whereas PilT is 
antagonistically involved in retraction of the pilus [65]. 
PilT is furthermore required for twitching motility [66] and 
intimate adhesion on host cells [67]. PilQ, another 
protein involved in pilus retraction, requires PilW to 
anchor in the outer cell membrane. The genes pilQ and 
pilW are located in one gene cluster together with pilP, 
pilM, pilN, and pilO, whose exact role in the tfp 
biogenesis are not entirely understood [68]. Likewise, the 
role of PilC is not fully understood even though it is 
shown that pilC null mutants are impaired in pilus 
expression, and it has been assumed that PilC acts 
antagonistically to PilT [66, 69]. PilC1 has been 
demonstrated to be involved in the adhesion to host cells 
[70, 71]. Several other proteins, such as PilH, PilI, PilJ, 
PilK, PilV, PilX, and ComP, are also targets of the 
prepilin peptidase and are, in the case of ComP, PilV, 
and PilX, also involved in host-cell interaction and 
adhesion [72, 73]. 
The outer membrane proteins known as Opa and Opc 
are another class of major adhesins. Opc interacts with 
cytoskeletal α-actinin of host cells and is therefore also 
an effective invasin [74]. N. meningitidis possesses four 
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Opa genes (opaA, opaB, opaC, and opaD) [47]. 
Encoding identical or different Opa proteins, they 
express up to four different Opa variants simultaneously 
[75]. Opa proteins play a central role in developing IMD, 
since they are known to mediate bacterial adherence 
and to modulate human cellular immunity [76, 77]. 
In addition to those major adhesins, there is a class of 
so-called minor adhesins including the Neisseria hia 
homolog A (NhhA), the adhesion and penetration protein 
(App), and the neisserial adhesin A (NadA) [50]. NhhA 
and App are homologous to the autotransporterproteins 
Hia/Hsf and Hap of Haemophilus influenzae [78-80]. 
NhhA is predominantly present in invasive strains, 
whereas App is found in carrier and invasive strains 
[79, 80]. Nevertheless, both are reported to mediate 
adhesion to host cells [79, 80]. Also frequently found in 
hyperinvasive lineages is NadA, an oligomeric coiled-coil 
adhesin (Oca) that directly interacts with protein 
receptors on epithelial cells [81].  
Thirteen capsular polysaccharides have been described 
but only six (A, B, C, W135, X, Y) are significantly 
associated to systemic infections [13]. The 
polysaccharide capsule is the main virulence 
Introduction 
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determinant in N. meningitidis [82]. The capsules differ in 
the polysaccharides they are composed of. While the 
serogroup A strain WUE2594 expresses homopolymeric 
(α1→6) N-acetylmannosamine 1-phosphate poly-
saccharide, the serogroup C strain 8013 expresses 
homopolymers of N-acetylneuraminic acid with (α2→9)- 
linkages, which are partially O-acetylated [13]. The 
capsule sterically inhibits the interaction of most 
adhesins with host cells but it does not prohibit the 
adhesion mediated by NhhA, App, NadA [50], or the 
tfp-mediated adhesion. In fact, the tfp appears to be 
required for adhesion in the presence of a capsule [14].  
3.5 Aims of the study 
To reveal the impact of the CRISPR/Cas system of 
N. meningitidis on the interaction to host cells, this study 
examines the adhesion and invasion of cas9, rnc, 
tracrRNA, and CRISPR array deletion mutants in the 
strains 8013 and WUE2594 on Detroit562 human 
nasopharyngeal cells.  
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4 Materials 
4.1 Laboratory equipment 
The following Table 4.1 enlists the laboratory equipment 
used in this study in alphabetical order. The states of 
registered business addresses are abbreviated by 
ISO-3166-1 alpha-2 country codes.  
Table 4.1 Laboratory equipment 
Device Type Manufacturer 
Agarose gel 
electrophoresis 
chamber 
MINI-BASIC Cti, Idstein DE 
Agarose gel 
electrophoresis 
chamber 
Electrophoresis 
chamber ‘Maxi’ 
Von Keutz, 
Reiskirchen DE 
Agarose gel 
electrophoresis 
chamber 
SubCell® GT Bio-Rad, Dreireich DE 
Analytical balance ABT 120-5DM Kern & Sohn, Balingen DE 
Analytical balance P-1200 
Mettler-Toledo, 
Greifensee CH 
Bunsen burner Fireboy (electric) Tecnomara, Zürich CH 
Bio Hazard bag Ref. 86.1203 Sarstedt, Nümbrecht DE 
Centrifuge (4 °C) Megafuge 1.0 R Haraeus, Hanau DE 
Materials 
 
19 
Device Type Manufacturer 
Centrifuge for cell 
culture 
Megafuge 1.0 R Haraeus, Hanau DE 
Centrifuge 
(benchtop, 4 °C) 
Mikro Rapid Hettich, Tuttlingen DE 
Centrifuge 
(benchtop) 
Biofuge pico Haraeus, Hanau DE 
Centrifuge (-Mini) SproutTM 
Biozym, 
Hessisch Oldendorf DE 
Centrifuge tube 
15 ml 
Cellstar® Tubes 
15 ml 
Greiner bio-one 
Frickenhausen DE 
Centrifuge tube 
50 ml 
Cellstar® Tubes 
50 ml 
Greiner bio-one 
Frickenhausen DE 
Chronograph Ref. 38.2021 
TFA Dostmann, 
Wertheim DE 
Cryo tubes KV12 Hartenstein, Würzburg DE 
Cuvettes for 
photometer 
Nr. 67.742 Sarstedt, Nümbrecht DE 
Colony counter ProtoCOL 
Meintrup DWS, 
Lähden DE 
Cotton swabs Ref. 1030128 
Heinz Herenz, 
Hamburg DE 
Disposal bag Ref. 86.1197 Sarstedt, Nümbrecht DE 
OD600 photometer WPA biowave Biochrom, Berlin DE 
Materials 
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Device Type Manufacturer 
Heating block VLM Q1 VLM, Bielefeld DE 
Hemocytometer ZK-03 Hartenstein, Würzburg DE 
Imaging system  ChemiDoc MP Bio-Rad, Dreieich DE 
Incubator (37 °C) 
Haraeus 
Kelvitron® t 
Haraeus, Hanau DE 
Incubator 
(37 °C/ 5% CO2) 
Haraeus 6000  Haraeus, Hanau DE 
Incubator 
(37 °C/ 5% CO2) for 
cell culture 
MCO-20AIC SANYO, Oizumi-Machi JP 
Incubation hood CERTOMAT® H B. Braun, Melsungen DE 
Inoculation loop 
Ref. 
86.1562.010 
Sarstedt, Nümbrecht DE 
Laboratory film Parafilm M Bemis, Neenah US 
Magnetic stirrer  IKAMAG® RCT IKA®, Staufen DE 
Membrane pump Typ 400057 ILMVAC, Ilmenau DE 
Microscope Wilovert® WILL, Wetzlar DE 
Microcentrifuge 
tubes 0.5 ml 
Ref. 72.704 Sarstedt, Nümbrecht DE 
Microcentrifuge 
tubes 1 ml 
Ref. 72.706 Sarstedt, Nümbrecht DE 
Microcentrifuge Ref. 72.695.500 Sarstedt, Nümbrecht DE 
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Device Type Manufacturer 
tubes 2 ml 
Microwave R-941STW Sharp, Osaka JP 
Nitrocellulose 
Transfer Membrane 
Ref. 10401196 
GE Healthcare, 
Freiburg DE 
Oven OV 5 Biometra, Göttingen DE 
PCR thermocycler  
T3 
Thermocycler 
Biometra, Göttingen DE 
pH indicator strips PH33 Hartenstein, Würzburg DE 
Pipette 10 µl 
Research plus, 
0.5-10 µl 
Eppendorf, Hamburg DE 
Pipette 100 µl 
Research plus, 
10-100 µl 
Eppendorf, Hamburg DE 
Pipette 1000 µl 
Research plus, 
100-1000 µl 
Eppendorf, Hamburg DE 
Pipette controller Accu-jet® BRAND, Wertheim DE 
Pipette controller Accu-jet® pro BRAND; Wertheim DE 
Pipette tip 10 µl Ref. 70.1115 Sarstedt, Nümbrecht DE 
Pipette tip 200 µl Ref. 70.760.002 Sarstedt, Nümbrecht DE 
Pipette tip 1000 µl Ref. 70.762 Sarstedt, Nümbrecht DE 
Power supply 
EV243 Consort 
Power Supply 
Consort, Turnhout BE 
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Device Type Manufacturer 
Power supply  
Standard Power 
Pack P25 
Biometra, Göttingen DE 
Protective gloves 
Peha-soft nitrile 
Fino L 
Hartmann, 
Heidenheim DE 
Protein gel 
electrophoresis 
Mini-Protean Bio-Rad, Dreieich DE 
Safety cabinet Safe 2020 1.8 
Thermo Scientific, 
Frankfurt DE 
Safety cabinet for 
cell culture 
NUAIRE  
Thermo Scientific, 
Frankfurt DE 
Serological pipette 
5 ml 
Ref. 
86.1253.001 
Sarstedt, Nümbrecht DE 
Serological pipette 
5 ml 
Ref. 
86.1254.001 
Sarstedt, Nümbrecht DE 
Serological pipette 
5 ml 
Ref. 
86.1685.001 
Sarstedt, Nümbrecht DE 
Semi-dry blotter PEGASUS S PHASE, Lübeck DE 
Shaker CERTOMAT® U B. Braun, Melsungen DE 
Shaker Phero Shaker 
Biotec-Fischer, 
Reiskirchen DE 
Spectrophotometer 
PEQLAB, 
ND-1000 
VWR, Erlangen DE 
Spectrophotometer Multiskan EX 
Thermo Scientific, 
Frankfurt DE 
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Device Type Manufacturer 
Surgical face mask 
Foliodress mask 
loop 
Hartmann,  
Heidenheim DE 
Thermoshaker 
Thermomixer 
5436 
Eppendorf, Hamburg DE 
UV crosslinker 18000 
Life Technologies, 
Darmstadt DE 
Vortex mixer REAX 2000 Heidolph, Schwabach DE 
Waterbath for cell 
culture 
WB 10 
Memmert,  
Schwabingen DE 
Waterbath WB 7 
Memmert,  
Schwabingen DE 
 
4.2 Chemicals and consumables 
Standard laboratory chemicals were purchased from 
AppliChem (Darmstadt DE), Merck (Darmstadt DE), 
Carl Roth (Karlsruhe DE), Roche (Mannheim DE) or 
Sigma-Aldrich (Schnelldorf DE). All specific reagents are 
listed alphabetically in Table 4.2.   
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Table 4.2 Specific reagents 
Reagent Source 
3-propanesulfonic acid (MOPS) 
AppliChem,  
Darmstadt DE 
Ammonium persulfate (APS) Roth, Karlsruhe DE 
Anti-Digoxidenin-AP Fab fragments 
(Anti-DIG-ATP) 
Roche, Mannheim DE 
Bromphenol blue Merck, Darmstadt 
β-mercaptoethanol (β-ME) Roth, Karlsruhe DE 
Chloroform ultra pure AppliChem, Darmstadt DE 
Crystal violet BD, Heidelberg DE 
ddH2O B.Braun, Melsungen DE 
DIG DNA labelling mix  Roche, Mannheim DE 
Dithiothreitol (DTT) AppliChem, Darmstadt DE 
Ethylenediaminetetraacetic acid 
(EDTA) 
AppliChem, Darmstadt DE 
Ethanol absolute AppliChem, Darmstadt DE 
Formaldehyde solution, 36.5-38% 
Sigma-Aldrich, 
Schnelldorf DE 
Formamide, deionized AppliChem, Darmstadt DE 
GelRed™ Biotium, Fremont US 
Materials 
 
25 
Reagent Source 
Hexanucleotide mix (10x) Roche, Mannheim DE 
Nonfat dried milk powder AppliChem, Darmstadt DE 
Nuclease-free water Ambion, Austin US  
Polyacrylamide (PAA):  
Rotiphorese Gel 30 
Roth, Karlsruhe DE 
Polyacrylamide (PAA):  
Rotiphorese Gel 40 
Roth, Karlsruhe DE 
Sodium dodecyl sulfate (SDS) pellets Roth, Karlsruhe DE 
Tetramethylethylendiamine (TEMED) Roth, Karlsruhe DE 
Trishydroxymethylaminomethane 
(TRIS) 
Sigma-Aldrich, 
Schnelldorf DE 
Triton-X 100% Roth, Karlsruhe DE 
Xylene cyanole  
Sigma-Aldrich, 
Schnelldorf DE 
 
Standard consumables were purchased from Ambion 
(Austin US), Biozym (Hessisch Oldendorf DE), 
Eppendorf (Wesseling-Berzdorf DE), Greiner bio-one 
(Frickenhausen DE), Hartenstein (Würzburg DE) and 
Sarstedt (Nümbrecht DE). All specific consumables are 
listed alphabetically in Table 4.3.  
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Table 4.3 Special consumables 
 Application Product Source 
 
Agarose-gels 
UltraPure™ 
agarose 
Life Technologies, 
Darmstadt DE 
dNTPs   
 
PCR amplification 
100mM dNTP set 
(dATP, dCTP, 
dGTP, dTTP) 
Sigma-Aldrich, 
Schnelldorf DE 
Reaction buffers   
 
for Taq polymerase 
ThermoPol 
reaction buffer 
New England Biolabs,  
Frankfurt DE 
 for Q5® 
polymerase  
Q5 reaction buffer 
New England Biolabs,  
Frankfurt DE 
 for restriction 
enzymes 
CutSmart® Buffer, 
NEBuffer 3.1 
New England Biolabs,  
Frankfurt DE 
 
for T4 DNA Ligase 
T4 DNA Ligase 
Buffer 
New England Biolabs,  
Frankfurt DE 
Oligos   
 
PCR amplification 
DNA 
oligonucleotides 
Sigma-Aldrich, 
Schnelldorf DE 
Ladders   
 
 
DNA 
HyperLadder™ 
1kb 
Bioline, 
Luckenwalde DE 
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 Application Product Source 
 
 
DNA Molecular 
Weight Marker VII, 
DIG-labeled 
Roche, 
Mannheim DE 
 
 
PageRuler™ 
Prestained Protein 
Ladder, 10 to 180 
kDa 
Life Technologies, 
Darmstadt DE 
Blotting   
 
Southern blot 
Amersham 
Hybond™-N+ 
GE Healthcare, 
Freiburg DE 
Antibodies   
 
First antibody 
Monoclonal Anti-
polyhistidine 
antibody produced 
in mouse 
Sigma-Aldrich, 
Schnelldorf DE 
 
Second antibody 
Anti-Mouse IgG-
Peroxidase 
antibody produced 
in rabbit  
Sigma-Aldrich, 
Schnelldorf DE 
Varying Applications   
 Static biofilm 
formation 
96 Well microtiter 
plate 
Sarstedt, 
Nümbrecht DE 
 
Cell culturing 
TC Flask T75 
standard 
Sarstedt, 
Nümbrecht DE 
 Cell 
invasion/adhesion 
24-well cell culture 
plates 
Sarstedt, 
Nümbrecht DE 
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4.3 Kits 
All kits are listed in Table 4.4 ordered by purpose. 
Table 4.4 Kits  
Application Product Source 
DNA extraction 
Invisorb Spin 
DNA Extraction 
Kit 
STRATEC Biomedical AG,  
Birkenfeld DE 
gDNA isolation 
QIAamp DNA 
Mini Kit 
Qiagen, Hilden DE 
PCR purification  
MSB Spin 
PCRapace 
STRATEC Biomedical AG, 
Birkenfeld DE 
Plasmid isolation 
QIAprep Spin 
Miniprep Kit 
Qiagen, Hilden DE 
 
4.4 Enzymes 
The following Table 4.5 lists all enzymes used in this 
study.  
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Table 4.5 Enzymes 
Enzyme Source 
DNase I, RNase-free 
Thermo Scientific, 
Schwerte DE 
Klenow enzyme Roche, Mannheim DE 
Lysozyme Roth, Karlsruhe DE 
Restriction endonucleases 
New England Biolabs,  
Frankfurt DE 
T4 DNA ligase 
New England Biolabs,  
Frankfurt DE 
Taq DNA polymerase 
New England Biolabs,  
Frankfurt DE 
Q5® High-Fidelity DNA polymerase 
New England Biolabs,  
Frankfurt DE 
 
4.5 Buffers and Solutions 
If not indicated otherwise, utilized reagents were 
purchased from Carl Roth (Karlsruhe DE), Difco 
(Heidelberg DE), Merck (Darmstadt DE), or Sigma-
Aldrich (Steinheim DE). 
Unless stated otherwise, all solutions and buffers were 
sterilized by autoclaving at 121 °C, 1 bar for 20 minutes. 
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For various microbiological and cell culture methods 1x 
Phosphate-buffered saline (PBS, Table 4.6) was used. It 
has final concentrations of 2.6 mM potassium chloride 
(KCl), 1.4 mM potassium phosphate monobasic 
(KH2PO4), 137.9 mM sodium chloride (NaCl) and 8.0 mM 
sodium phosphate dibasic (Na2HPO4). The following 
Table 4.6 lists the instructions for preparation. 
Table 4.6 Phosphate-buffered saline 
 Content Preparation 
10x PBS  
 GIBCO® DPBS 1 pellet 
 ddH2O ad 1000 ml 
1x PBS  
 10x PBS 100 ml 
 ddH2O ad 1000 ml 
 
For long term storage of bacteria, a glycerol based 
freezing medium was used. The following Table 4.7 lists 
the instructions for preparation.  
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Table 4.7 Freezing medium 
 Content Preparation 
 Glycerol, 86% 233 ml 
 
Caso-Bouillon  
(BD, Heidelberg DE)  
15 g 
 ddH2O ad 500 ml 
 
For electrophoretic separation of DNA in agarose gels 
1x TAE (Table 4.8) was used as running buffer. The 
6x DNA loading buffer (Table 4.8) was stored at 4 °C in a 
1.5 ml microcentrifuge tube until usage. For DNA 
staining loaded agarose gels were bathed in GelRed™ 
solution (Table 4.8) for 30-45 minutes. 
Table 4.8 Buffers and solutions used for electrophoretic 
separation of DNA 
 Content Preparation 
50x TAE (TRIS-acetate EDTA)  
 TRIS 242 g 
 100% acetic acid 57.1 ml 
 0.5 M EDTA (pH 8.0) 100 ml 
 ddH2O 
ad 1000 ml,  
adjust pH to 8.3 
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 Content Preparation 
1x TAE  
 50x TAE 40 ml 
 ddH2O ad 2000 ml 
6x DNA loading buffer  
 Saccharose 40 g 
 Glycine 30 ml  
 Bromphenolblue 100 mg 
 Xylencyanol 100 mg 
 ddH2O ad 100 ml 
GelRed™ solution  
 ddH2O 150 ml 
 GelRed™ 15 µl 
 
The composition of all buffers and solutions used for 
Southern blots is given in Table 4.9.  
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Table 4.9 Buffers and solutions used for Southern blots 
 Content Preparation 
10x Blocking reagent  
 
Blocking reagent 
(Roche, Mannheim DE) 
10 g 
 1x Maleic acid buffer 
ad 100 ml,  
storage at -10 °C 
1x Blocking solution  
 10x blocking reagent 10 ml 
 1x Maleic acid buffer 90 ml 
Antibody solution  
 
Anti-DIG-AP (Roche, Mannheim DE) 1:10000 in 1x Blocking 
solution 
 Storage at 4 °C 
CSPD working solution 
 
CSPD (Roche, Mannheim DE) 1:100 in detection buffer 
Storage at 4 °C 
Coomassie staining solution 
 10 % acetic acid 
 60 mg/l Coomassie Blue R-250 
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 Content Preparation 
Gel fixing solution 
 25% isopropanolol 
 10% acetic acid 
 in ddH2O 
Detection buffer  
 1 M TRIS/HCl, pH 9.6 100 ml (0.1M) 
 5M NaCl 20 ml (0.1M) 
 ddH2O ad 1000 ml 
High SDS hybridisation buffer  
 20x SSC 125 ml 
 10x Blocking reagent 100 ml 
 SDS 35 g 
 10% N-Lauroylsarcosine 0.5 ml 
 
5x Sodium phosphate buffer,  
pH 7.0 
25 ml 
 ddH2O 
ad 500 ml,  
storage at -20 °C 
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 Content Preparation 
1x Maleic acid buffer  
 Maleic acid 23.2 g 
 NaCl 17.53 g  
 ddH2O 
ad 2000 ml,  
adjust pH to 7,5 
20x Saline-Sodium-Citrate (SSC)  
 NaCl 175.5 g 
 Sodium citrate 88.2 g 
 ddH2O 
ad 1000 ml,  
adjust pH to 7.0 
Stringent washing buffer I  
 20x SSC 100 ml 
 10x SDS 10 ml 
 ddH2O ad 1000 ml 
Stringent washing buffer II  
 20x SSC 5 ml 
 10x SDS 10 ml 
 ddH2O ad 1000 ml 
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 Content Preparation 
Washing buffer  
 1x Maleic acid buffer 1000 ml 
 Tween 20 3 ml 
 ddH2O ad 2000ml 
 
Table 4.10 lists all buffers, gels and solutions used for 
electrophoretic separation of denatured proteins using 
SDS polyacrylamide gels (SDS PAGE). 
Table 4.10 SDS PAGE 
 Content Preparation 
1x Electrophoresis buffer  
 10x Lämmli 200 ml 
 10% SDS 10 ml 
 ddH2O ad 2000 ml 
10x Lämmli  
 TRIS 30 g 
 Glycine 144 g 
 ddH2O 
ad 1000 ml, 
adjust pH to 8.3 
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 Content Preparation 
Lower TRIS  
 TRIS 90.85 g 
 10% SDS 20 ml 
 ddH2O 
ad 500 ml, 
storage at 4 °C 
Upper TRIS  
 TRIS 30.3 g 
 10% SDS 20 ml 
 ddH2O 
ad 500 ml,  
storage at 4 °C 
Sample buffer  
 Β-mercaptoethanol 5 ml 
 20% SDS 10 ml 
 Glycerol 25 ml 
 Bromphenol blue a spatula tip 
 0.5 M TRIS/HCl pH 6.8 
ad 100 ml, 
storage at -20 °C 
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 Content Preparation 
Separation gel 12.5%  
 Lower TRIS 3 ml 
 PAA 30 5 ml 
 10% APS 60 µl 
 TEMED 20 µl 
 ddH2O 4 ml, yielding 2 gels 
Loading gel  
 Upper TRIS 1.25 ml 
 PAA 30 0.75 ml 
 10% APS 35 µl 
 TEMED 20 µl, yielding 2 gels 
 
4.6 Culture media 
Unless stated otherwise, culture media were sterilized by 
autoclaving at 121 °C with 1 bar for 20 minutes or 
filtrated through 0.2 µm membrane filters (Sarstedt, 
Nümbrecht DE).  
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4.6.1 Liquid media for N. meningitidis 
cultivation 
In this study proteose peptone medium (PPM) was used 
as rich medium for N. meningitidis. The following 
Table 4.11 lists its preparation. To obtain PPM+ 
(Table 4.13) the supplements (Table 4.12) were added 
right before use. 
Table 4.11 Composition of PPM 
Content Preparation 
Bacto™ proteose peptone (BD, Heidelberg DE) 15 g 
NaCl 5 g 
Potato starch (Honeywell, Offenbach DE)  0.5 g 
KH4PO4 4 g 
K2HPO4 (dipotassium phosphate) 1 g 
ddH2O 
ad 1000 ml, 
adjust to pH 7.8 
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Table 4.12 Supplements of PPM+ medium 
 Content Preparation 
8.4% NaHCO3  
 NaHCO3 21 g 
 ddH2O ad 250 ml 
2 M MgCl2  
 MgCl2 x 6 H2O 101.7 g 
 ddH2O ad 250 ml 
PolyViteX (bioMèrieux, Nürtingen DE)  
 Cobalamin 0.1 mg/l 
 L-glutamine 100 mg/l 
 Adenine 10 mg/l 
 Guaninchlorhydrate 0.3 mg/l 
 4-Aminobenzoic acid (PABA) 0.13 mg/l 
 L-cystine 11 mg/l 
 Diphosphopyridinnucleotid, oxidized 2.5 mg/l 
 Cocarboxylase 1.04 mg/l 
 Iron(III)nitrate 0.2 mg/l 
 Thiamine chlorhydrate 0.03 mg/l 
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 Content Preparation 
 Cysteine chlorhydrate 259 mg/l 
 
Table 4.13 Composition of PPM+ 
Content Preparation 
PPM  98 ml 
8.4% NaHCO3 500 µl 
2 M MgCl2 500 µl 
PolyViteX 1 ml 
 
The gonococcus base liquid (GCBL) medium was used 
for transformation of N. meningitidis. The following 
Table 4.14 lists its composition. To obtain GCBL+ 
(Table 4.16) the supplements (Table 4.15) were added 
right before use. 
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Table 4.14 Composition of GCBL medium 
Content Preparation 
Bacto™ proteose peptone  
(BD, Heidelberg DE) 
15 g 
K2HPO4 4 g 
KH2PO4 1 g 
NaCl 1g 
ddH2O ad 1000 ml 
 
Table 4.15 Supplements of GCBL++ medium 
 Content Preparation 
Kellogg’s supplement I  
 Glucose 40 g 
 L-glutamine 1 g 
 Thiamine pyrophosphate 2 mg 
 ddH2O 
ad 100 ml, 
storage at -20 °C 
Kellogg’s supplement II   
 Iron(III) nitrate 50 mg 
 ddH2O 
ad 100 ml,  
storage at -20 °C 
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 Content Preparation 
Sodium bicarbonate (NaHCO3)  
 NaHCO3 0.42 g 
 ddH2O ad 100 ml 
 
Table 4.16 Composition of GCBL++ medium 
Content Preparation 
GCBL  97.9 ml 
Kellogg’s I 1 ml 
Kellogg’s II 100 µl 
NaHCO3 1 ml 
 
4.6.2 Solid media for N. meningitidis 
cultivation 
For cultivation of N. meningitidis strains on solid media, 
supplemented gonococcus base (GCB++) agar plates or 
Columbia agar plates with 5% sheep blood (COS plates; 
BD, Heidelberg DE) were used. The following Table 4.17 
lists the composition of GCB++ agar plates. 
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Table 4.17 Composition of GCB++ agar 
Content Preparation 
Difco™ GC Medium Base  
(BD, Heidelberg DE) 
36.25 g 
Agar 1.25 g 
ddH2O ad 1000 ml 
Kellogg’s I 
10 ml, added after 
autoclavation 
Kellogg’s II 
1 ml, added after 
autoclavation 
 
4.6.3 E. coli cultivation 
For cultivation of E. coli in liquid medium Luria-Bertani 
(LB) medium was used. Table 4.18 lists its composition. 
For cultivation on solid media 1.5% agar was added to 
the liquid medium before autoclaving. For chemical 
transformations of E. coli Super Optimal broth with 
Catabolic repression (SOC; Table 4.20) was used. To 
obtain SOC the supplements were added to Super 
Optimal Broth (SOB; Table 4.19) right before use. 
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Table 4.18 Composition of LB medium 
Content Preparation 
Peptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
ddH2O ad 1000 ml 
 
Table 4.19 Composition of Super Optimal Broth (SOB) 
medium 
Content Concentration 
Bacto™ tryptone 2% Bacto™ yeast extract  
(BD, Heidelberg DE) 
0.5% 
NaCl 10 mM 
KCl 2.5 mM 
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Table 4.20 Composition of Super Optimal broth with 
Catabolic repression (SOC) medium 
Content Preparation 
SOB 5 ml 
2 M MgCl2 25 µl 
1 M MgSO4 50 µl 
1 M glucose 100 µl 
 
4.6.4 Cell culture media and solutions 
Table 4.21 lists solutions and media used for cell 
culturing with their intended usage and the source of 
purchase  
Table 4.21 Solutions and media used for cell culture 
Product Application Source 
MEM Eagle 
(EMEM) 
Cell culture medium LONZA, Basel CH 
Fetal calf serum 
(FCS) 
Medium supplement 
Thermo Fisher, 
Frankfurt DE 
Nonessential 
amino acids 
(NEAA) 
Medium supplement LONZA, Basel CH 
Sodium pyruvate 
(NaPyr 100 mM) 
Medium supplement LONZA, Basel CH 
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Product Application Source 
Trypsin-EDTA 
(0.05%) 
Dissociation of cells 
Thermo Fisher, 
Frankfurt DE 
Gentamicin  
(10 mg/ml) 
Antibacterial agent Biochrom, Berlin DE 
Saponin (20%) 
Permeabilization of 
cells 
SERVA,  
Heidelberg DE 
RPMI 1640 + 
Glutamax™ -I 
Cell culture medium 
Thermo Fisher, 
Frankfurt DE 
Dimethyl sulfoxide 
(DMSO) 
Cell cryopreservation Roth, Mannheim DE 
 
As standard cell culture medium EMEM+++ was used. 
Table 4.22 lists its composition. 
Table 4.22 Composition of EMEM+++ 
Content Preparation 
EMEM 500 ml 
FCS 50 ml 
NEAA 5 ml 
NaPyr 5 ml 
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Given in Table 4.23 are the concentrations of 
components of EMEM supplemented with 1% NEAA and 
1% sodium pyruvate (100 mM) calculated using the 
manufacturers’ published formulation. Due to the 
addition of 10% FCS the concentrations of amino acids 
are likely higher in EMEM+++ (see Table 4.22) but 
because of its natural origin the exact formulation of FCS 
underlies fluctuations and cannot be assessed exactly. 
Table 4.23 Formulation of EMEM supplemented with 1% 
NEAA and 1% sodium pyruvate (100mM) 
Component Concentration (g/l) 
Inorganic Salts 
CaCl2 0.196 
MgSO4 0.096 
KCl 0.392 
NaHCO3 1.471 
NaCl 6.667 
NaH2PO4 H2O 0.137 
Amino acids 
L-Alanine 0.017 
L-Arginine HCl 0.124 
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Component Concentration (g/l) 
L-Asparagine H2O 0.028 
L-Aspartic Acid 0.026 
L-Cystine 2HCl 0.031 
L-Glutamic Acid 0.029 
L-Glutamine 0.286 
Glycine 0.007 
L-Histidine HCl H2O 0.041 
L-Isoleucine 0.051 
L-Leucine 0.051 
L-Lysine HCl 0.071 
L-Methionine 0.015 
L-Phenylalanine 0.032 
L-Proline 0.023 
L-Serine 0.021 
L-Threonine 0.047 
L-Tryptophan 0.01 
L-Tyrosine 2Na 2H2O 0.051 
L-Valine 0.046 
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Component Concentration (g/l) 
Vitamins 
Choline Chloride 0.001 
Folic Acid 0.001 
myo-Inositol 0.002 
Nicotinamide 0.001 
D-Pantothenic Acid (hemicalcium) 0.001 
Pyridoxine HCl 0.001 
Riboflavin 0.001 
Thiamine HCl 0.001 
Other  
D-Glucose 0.98 
Phenol Red, Sodium Salt 0.01 
Sodium Pyruvate 0.216 
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For long-term storage, 1x 106 cells were resuspended in 
freezing medium (Table 4.24) and stored in liquid 
nitrogen at -196 °C.  
Table 4.24 Composition of cell freezing medium 
Content Preparation 
RPMI 1640 + Glutamax™-I 50 ml 
FCS 30 ml 
DMSO 20 ml 
 
In some experiments the cell culture medium RPMI+ was 
used. Table 4.25 lists its composition. 
Table 4.25 Composition of RPMI+ 
Content Preparation 
RPMI 1640 + Glutamax™-I 500 ml 
FCS 50 ml 
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4.7 Antibiotic supplements 
Table 4.26 lists the antibiotics and the concentrations 
used in this study. 
Table 4.26 Antibiotics 
Antibiotic 
Final 
concentration 
(µg/ml) 
Stock 
concentration 
(µg/ml) 
Solvent 
 E.c.a N.m.b E.c.a N.m.b  
Ampicillin 100 - 100 - ddH2O 
Kanamycin 30 100 30 100 ddH2O 
Erythromycin 
250 7 100 7 100% 
Ethanol 
Chloramphenicol 
30 7 30 7 70% 
Ethanol 
afor E. coli 
bfor N. meningitidis 
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4.8 Oligonucleotides 
The oligonucleotides used in this study are listed in 
Table 4.27.  
Table 4.27 Sequences of oligonucleotides 
IDa Sequence (5’-3’)b Target site 
242 
AATACGAC 
TCACTATA 
GGGC 
pBluescript-SK 
243 
ACCATGAT 
TACGCCAA 
GC 
pBluescript-SK 
328 
GGTATTGA 
TAATCCTG 
ATATGAA 
Tn903 Kanamycin 
resistance cassette 
329 
GATGGTCG 
GAAGAGGC 
ATAAATT 
Tn903 Kanamycin 
resistance cassette 
550 
gcgcgcGG 
ATCCBamHIT 
CCAACAGG 
TTGGCAAT 
CCGCAAT 
WUE2594/ 8013 
downstream rnc 
551 
gcgcgcGA 
ATTCEcoRIG 
GCGGCGCG 
TGAATATG 
CCGTCTGA 
WUE2594/ 8013 
downstream rnc 
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IDa Sequence (5’-3’)b Target site 
552 
gcgcgcGA 
ATTCEcoRIT 
ACCGTCTT 
CCGCAAAA 
AACAGCC 
WUE2594/ 8013 
upstream rnc 
554 
gcgcgcAA 
GCTTHindIII 
TTCGCTGC 
CGATTTCG 
TTGGTGA 
WUE2594/ 8013 
upstream rnc 
617 
ATTCGTTG 
GAAACCAG 
CTCGAA 
WUE2594/ 8013 rnc locus 
618 
ATATCTTC 
GGGATACA 
TCGGCACG 
WUE2594/ 8013 rnc locus 
729 
gcgcgcGG 
ATCCBamHIA 
AATCGCCT 
GTCTGTAA 
GGCATG 
WUE2594/ 8013 upstream 
tracrRNA 
730 
gcgcgcGA 
ATTCEcoRIG 
TATATAAA 
TAAGACAA 
TAAGATAT 
ATTATCA 
WUE2594 upstream 
tracrRNA 
732 
gcgcgcGA 
ATTCEcoRIT 
GCCGTCTG 
AAACCGAT 
TTTGGGCT 
T 
WUE2594 downstream 
tracrRNA 
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IDa Sequence (5’-3’)b Target site 
733 
gcgcgcAA 
GCTTHindIII 
AACTGTCG 
AAACTCAA 
ACCGCAA 
WUE2594 downstream 
tracrRNA 
739 
AATCTTTG 
CGGCTGAA 
CGTATG 
WUE2594 tracrRNA locus 
740 
ATCGAACC 
GGTGCGGC 
TCATTGA 
WUE2594 tracrRNA locus 
833 
gcgcgcGA 
ATTCEcoRIG 
TATATAAA 
TAAGACAA 
TCAGATAT 
8013 upstream tracrRNA 
834 
gcgcgcAA 
GCTTHindIII 
AAGTCCGCC 
AAATCGCAC 
CGACCA 
8013 downstream tracrRNA 
835 
gcgcgcGA 
ATTCEcoRIT 
GCCGTCTG 
AAACCGGT 
TTTTGGGC 
T 
8013 downstream tracrRNA 
903 
GCCGTCTG 
AAGCCGCA 
AGACAGCG 
8013 cas9 locus 
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IDa Sequence (5’-3’)b Target site 
904 
TATGAAAC 
AAGCCTAA 
TGCAGGCA 
8013 cas9 locus 
905 
TCGAAACT 
CAAACCGC 
AAGACAGC 
WUE2594 cas9 locus 
906 
TATGAAAC 
AAGCCTAA 
TGCAGGTA 
WUE2594 cas9 locus 
935 
CGGGAAGA 
TGCGTGAT 
CTGA 
Kanamycin probe 
936 
CCTCTTCC 
GACCATCA 
AGCA 
Kanamycin probe 
970 
TTCGCCCA 
AATCGCAG 
GAAATGA 
WUE2594/ 8013 rnc 
971 
TGTTTTGA 
AACAGCAG 
GCACACG 
WUE2594/ 8013 rnc 
972 
GCAAATGC 
GGTTGTAG 
CTCCCTT 
WUE2594 CRISPR 
973 
CCCGACAC 
ATCCGTCA 
TCAACG 
WUE2594 CRISPR 
974 
AATCTTCC 
GCACTTCC 
AGGGGTT 
8013 CRISPR 
Materials 
 
57 
IDa Sequence (5’-3’)b Target site 
975 
CAAGTGCG 
AGGCGCGT 
ATATTGT 
8013 CRISPR 
976 
TGCCGAAG 
CCTCAACA 
TTGATGG 
WUE2594/ 8013 cas9 
977 
TTGGCGTT 
TCTCAATT 
TCTTTGC 
WUE2594/ 8013 cas9 
988 
CCGAACCG 
CTGGCGCG 
TTAA 
8013 NMV0959 locus 
989 
ATTAATGC 
CGCCTCCG 
TCGG 
8013 porA locus 
1031 
GAAGCGAA 
CTCAATCC 
ATTCA 
8013 CRISPR locus 
1032 
CAATGGAA 
AGCTAATG 
TATTA 
8013 CRISPR locus 
1035 
gtttGGAT 
CCBamHIAGC 
CACGTTGT 
GTCTCAAA 
Tn903 Kanamycin 
resistance cassette 
1043 
gttttATG 
CATNsiIGG 
AATACGTT 
GGGGGAAA 
AC 
8013 rnc 
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IDa Sequence (5’-3’)b Target site 
1044 
gttttGGA 
TCCBamHIAA 
AGGCTCCA 
AAAGGAGC 
CTTTTCAT 
TTCTTTTT 
CCTCTTCA 
GC 
8013 rnc 
1045 
gttttATG 
CATNsiITTC 
TTATTTCA 
AATCTGTG 
ACAC 
8013 CRISPR 
1046 
gttttGGA 
TCCBamHIAA 
AGGCTCCA 
AAAGGAGC 
CTTTAATA 
AGGATTTC 
CCGTCGAA 
GT 
8013 CRISPR 
1047 
gttttATG 
CATNsiICC 
GTAAACAA 
CGTTGCAA 
ATAA 
8013 tracrRNA 
1048 
gttttGGA 
TCCBamHIAA 
AGGCTCCA 
AAAGGAGC 
CTTTTAAA 
CGATGCCC 
CTTAAAGC 
AG 
8013 tracrRNA 
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IDa Sequence (5’-3’)b Target site 
1049 
CACTTTCC 
CTGTTTCT 
ATG 
cat Chloramphenicol 
resistance cassette 
1054 
GCCGTCTG 
AACGGGGC 
GGTGAAGC 
GGATAG 
pCompInd 
1055 
GCCGTCTG 
AACGAACC 
GCTGGCGC 
GTTAAACA 
pCompInd 
1110 
gtttttCA 
TATGNdeIAC 
GCGTCTTA 
AGGCGGCC 
cat Chloramphenicol 
resistance cassette 
1111 
gtttttTC 
TAGAXbaIGT 
CAACCGTG 
ATATAGAT 
TGAA 
cat Chloramphenicol 
resistance cassette 
1117 
gttttCAT 
ATGNdeICGC 
TGAGGTCT 
GCCTCGTG 
Tn903 Kanamycin 
resistance cassette 
1118 
gttttTCT 
AGAXbaIAGC 
CACGTTGT 
GTCTCAAA 
Tn903 Kanamycin 
resistance cassette 
1122 
CGAGCAAT 
ACAGCGGC 
AGATTTTC 
C 
8013 NMV1884 
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IDa Sequence (5’-3’)b Target site 
1123 
CTAAACCT 
AAAGTGAA 
TAGCTCAC 
TTATCAG 
ermC 
1227 
CGCCAAGA 
AGAAAACC 
GCAA 
8013 cas9 probe 
1228 
TTTCGCTG 
CCCAATAC 
CAGT 
8013 cas9 probe 
1229 
ATTGGCGC 
GAAAAATC 
GGAC 
8013 NMV0031 probe 
1230 
CCGCACTT 
TTTCTGAT 
GGGC 
8013 NMV0031 probe 
10509 
gcgcgcGG 
ATCCBamHIG 
TCAGCCGC 
GACGACTA 
CGGCGGC 
WUE2594/ 8013 upstream 
cas9 
10510 
gcgcgcGA 
ATTCEcoRIT 
TATTACTC 
CGTAAACA 
ACGTTGC 
WUE2594/ 8013 upstream 
cas9 
10511 
gcgcgcGA 
ATTCEcoRIA 
TTAATCTA 
TCCCTGTT 
TCAGACT 
8013 downstream cas9 
Materials 
 
61 
IDa Sequence (5’-3’)b Target site 
10512 
gcgcgcCT 
CGAGXhoITA 
GTTCAATG 
CGGCATTG 
ACGGCA 
8013 downstream cas9 
10515 
gcgcgcGA 
ATTCEcoRIA 
TTAATCTA 
TCCCTGTT 
TCAGGCG 
WUE2594 downstream 
cas9 
10516 
gcgcgcCT 
CGAGXhoITA 
GTTCAATG 
CGGCATTG 
ACGGCG 
WUE2594 downstream 
cas9 
11114 
gcgcgcGG 
ATCCBamHIC 
GGCAACAT 
TTCAGCAC 
CTTG 
WUE2594 downstream 
CRISPR 
11115 
gcgcgcGA 
ATTCEcoRIA 
CTTCGACG 
GGAAATCC 
TTAT 
WUE2594/ 8013 
downstream CRISPR 
11116 
gcgcgcGA 
ATTCEcoRIC 
AGCCGTTG 
CGATAAGC 
GAAC 
WUE2594/ 8013  
upstream CRISPR 
11306 
gcgcgcAA 
GCTTHindIII 
CTGGTCCA 
ACTTCAAT 
AGCGG 
WUE2594 upstream 
CRISPR 
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IDa Sequence (5’-3’)b Target site 
11443 
GGATCCBamHI 
CGTGATAC 
ATTTGTAC 
GAACA 
8013 downstream CRISPR 
11444 
AAGCTTHindIII 
CAGTTTGA 
GAGTAAAG 
CAGGG 
8013 upstream CRISPR 
11604 
TGCCGTCC 
AGTAACTG 
ATGTTCTT 
WUE2594 downstream 
CRISPR 
11605 
GCATCAAA 
CAACACCT 
CATCAAAA 
WUE2594 upstream 
CRISPR 
12662 
tattGACG 
TCAatIITTC 
TAGCCGTT 
GTGAGATG 
ATAAG 
8013 cas9 
12663 
tcgcTTAA 
TTAAPacIC 
GGACAGGC 
GGGCGTTT 
TTTC 
8013 cas9 
 
aID-number 0-9999 according to the AG SCHOEN oligonucleotide 
collection, 10000-99999 according to the common IMIB 
oligonucleotide collection 
bRestriction sites are underlined, small letters indicate nonsense-
nucleotides 
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4.9 Plasmids 
The plasmids used for cloning are listed in Table 4.28. 
Table 4.28 Utilized plasmids 
IDa Plasmid 
Description and 
Usage 
Res.b Reference 
315 pBluescript-
SK 
standard cloning vector Ampr Stratagene, 
La Jolla US 
 pBluescript 
II - SK (+) 
standard cloning vector Ampr Stratagene, 
La Jolla US 
 pGCC2 standard vector for 
complementation 
Eryr [83] 
 pCompInd standard vector for 
complementation 
Cmr [84] 
58 pUC4K Delivery plasmid 
harbouring kanamycin 
resistance cassette 
Kmr GE 
Healthcare, 
Freiburg DE  
5101 pBJ104 Kanamycin resistance 
cassette with EcoRI 
sites from pUC4K 
cloned between PCR 
product 10509/10510 
comprising 8013 cas9 
UP fragment and PCR 
product 10511/10512 
comprising 8013 cas9 
DOWN fragment into 
XhoI and BamHI sites 
of pBS-SK; used for 
8013 cas9 knockouts  
Ampr/ 
Kmr 
[45] 
Materials 
 
 
64 
IDa Plasmid 
Description and 
Usage 
Res.b Reference 
5117 pBJ102 Kanamycin resistance 
cassette with EcoRI 
sites from pUC4K 
cloned between PCR 
product 550/551 
comprising 8013 rnc 
UP fragment and PCR 
product 552/554 
comprising 8013 rnc 
DOWN fragment into 
HindIII and BamHI 
sites of pBS-SK; used 
for 8013 rnc 
knockouts  
Ampr/ 
Kmr 
[45] 
5124 pBJ107 Kanamycin resistance 
cassette with EcoRI 
sites from pUC4K 
cloned between PCR 
product 834/835 
comprising 8013 
tracrRNA UP fragment 
and PCR product 
833/729 comprising 
8013 tracrRNA DOWN 
fragment into HindIII 
and BamHI sites of 
pBS-SK; used for 8013 
tracrRNA knockouts  
Ampr/ 
Kmr 
[45] 
5105 pBJ106 Kanamycin resistance 
cassette with EcoRI 
sites from pUC4K 
cloned between PCR 
product 11443/11115 
comprising 8013 
Ampr/ 
Kmr 
this study 
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IDa Plasmid 
Description and 
Usage 
Res.b Reference 
CRISPR array UP 
fragment and PCR 
product 11116/11444 
comprising CRISPR 
array DOWN fragment 
into HindIII and BamHI 
sites of pBS-SK; used 
for 8013 CRISPR 
knockouts  
5238 pAH-1 PCR product 
1043/1044 comprising 
rnc (NMV-1713) of N. 
meningitidis 8013 
cloned between the 
NsiI and the BamHI 
sites of pCompInd; 
used for 8013 rnc 
complementation  
Ampr/ 
Cmr 
this study 
5239 pAH-2 PCR product 
1047/1048 comprising 
tracrRNA (genomic 
region 1916964 to 
1916858) of N. 
meningitidis 8013 
cloned between the 
NsiI and the BamHI 
sites of pCompInd; 
used for 8013 
tracrRNA 
complementation  
 
Ampr/ 
Cmr 
this study 
 pGCC2 PCR product 
12662/12663 
Ampr/ [45] 
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IDa Plasmid 
Description and 
Usage 
Res.b Reference 
cas9-comp comprising cas9 (NMV-
1993) of N. 
meningitidis 8013 
cloned between the 
AatII And the PacI sites 
of pGCC2; used for 
8013 cas9 
complementation  
Eryr 
5100 pBJ103 Kanamycin resistance 
cassette with EcoRI 
sites from pUC4K 
cloned between PCR 
product 10509/10510 
comprising WUE2594 
cas9 UP fragment and 
PCR product 
10515/10516 
comprising WUE2594 
cas9 DOWN fragment 
into XhoI and BamHI 
sites of pBS-SK; used 
for WUE2594 cas9 
knockouts  
Ampr/ 
Kmr 
this study 
5116 pBJ101 Kanamycin resistance 
cassette with EcoRI 
sites from pUC4K 
cloned between PCR 
product 550/551 
comprising WUE2594 
rnc UP fragment and 
PCR product 552/554 
WUE2594 rnc DOWN 
fragment into HindIII 
and BamHI sites of 
Ampr/ 
Kmr 
this study 
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IDa Plasmid 
Description and 
Usage 
Res.b Reference 
pBS-SK; used for 
WUE2594 rnc 
knockouts  
5125 pBJ108 Kanamycin resistance 
cassette with EcoRI 
sites from pUC4K 
cloned between PCR 
product 729/730 
comprising WUE2594 
tracrRNA UP fragment 
and PCR product 
732/733 comprising 
WUE2594 tracrRNA 
DOWN fragment into 
XhoI and BamHI sites 
of pBS-SK; used for 
WUE2594 tracrRNA 
knockouts  
Ampr/ 
Kmr 
this study 
5104 pBJ105 Kanamycin resistance 
cassette with EcoRI 
sites from pUC4K 
cloned between PCR 
product 11114/11115 
comprising WUE2594 
CRISPR UP fragment 
and PCR product 
11116/11306 
comprising WUE2594 
CRISPR DOWN 
fragment into HindIII 
and BamHI sites of 
pBS-SK; used for 
WUE2594 CRISPR 
knockouts  
Ampr/ 
Kmr 
this study 
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IDa Plasmid 
Description and 
Usage 
Res.b Reference 
5243 pAH-4 PCR product of 
1117/1118 comprising 
the Tn903 kanamycin 
resistance determinant 
of pUC4K cloned 
between the NdeI and 
XbaI sites of pCompInd 
Ampr/ 
Kmr 
this study 
5244 pAH-5 PCR product of 
1117/1035 comprising 
the Tn903 kanamycin 
resistance determinant 
of pUC4K cloned 
between the NdeI and 
BamHI sites of 
pCompInd 
Ampr/ 
Kmr/ 
Cmr 
this study 
5242 pAH-3 PCR product 
1110/1111 comprising 
the cat 
chloramphenicol 
resistance determinant 
cloned between the 
NdeI and XbaI sites of 
pCompInd 
Ampr/ 
Cmr 
this study 
 
aID-number according to the strain collection of the Institute for 
Hygiene and Microbiology (IHM), Würzburg 
bantibiotic resistance cassettes obtained by the strain; Kmr, 
kanamycin; Ampr, ampicillin; Eryr, erythromycin; Cmr, 
chloramphenicol 
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4.10 Microorganisms 
The strains used in this study are listed in Table 4.29. 
Figure 6.1 on page 117 depicts the genealogy of 8013 
strains used in this study. 
Table 4.29 Strains used in this study 
IDa MOb Strain 
relevant 
characteristics 
b.r.c 
Source/ 
Reference 
286 E.c. XL1-Blue 
MRF’ 
Δ((mcrA)183Δ(m
crCB-hsdSMR-
mrr)173 recA1 
endA1 gyrA96 
thi-1 hsdR17 
supE44 relA1 lac 
F´ proAB 
lacIqZ∆M15 Tn10 
Tetr 
- Stratagene, 
La Jolla US 
19 E.c. DH5 fhuA2 
lac(del)U169 
phoA glnV44 
Φ80' 
lacZ(del)M15 
gyrA96 recA1 
relA1 endA1 thi-1 
hsdR17 
- Thermo Fisher, 
Frankfurt DE 
29 N.m. WUE2594 wild type - Accession-No: 
FR774048.1 
[48] 
5098 N.m. WUE2594 ∆cas9::Kmr 1 this study 
5122 N.m. WUE2594 ∆tracrRNA::Kmr 1 this study 
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IDa MOb Strain 
relevant 
characteristics 
b.r.c 
Source/ 
Reference 
5114 N.m. WUE2594 ∆rnc::Kmr 1 this study 
5102 N.m. WUE2594 ∆CRISPR::Kmr 1 this study 
31 N.m. 8013 wild type - Accession-No: 
FM999788.1 
5099 N.m. 8013 ∆cas9::Kmr 3 [45] 
 N.m. 8013 ∆cas9::Kmr Eryr 2 [45] 
5123 N.m. 8013 ∆tracrRNA::Kmr 2 [45] 
5245 N.m. 8013 ∆tracrRNA::Kmr 
Cmr 
2 this study 
5115 N.m. 8013 ∆rnc::Kmr 2 [45] 
5246 N.m. 8013 ∆rnc::Kmr Cmr 2 this study 
5103 N.m. 8013 ∆CRISPR::Kmr 2 this study 
5247 N.m. 8013 Cmr 1 this study 
 N.m. 8013 ∆cas9::Kmr 
Ccas9 Eryr 
3 [45] 
5240 N.m. 8013 ∆tracrRNA::Kmr 
CtracrRNA Cmr 
2 this study 
5249 N.m. 8013 ∆tracrRNA::Kmr 
Ccas9 Eryr 
1 this study 
5248 N.m. 8013 ∆tracrRNA::Kmr 
CtracrRNA Cmr 
2 this study 
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IDa MOb Strain 
relevant 
characteristics 
b.r.c 
Source/ 
Reference 
Ccas9 Eryr 
5241 N.m. 8013 ∆rnc::Kmr Crnc 
Cmr 
2 this study 
 
aID-number according to the strain collection of the Institute for 
Hygiene and Microbiology (IHM), Würzburg 
bmicroorganism 
cNumber of biological replicates used for experiments 
Abbreviations: N.m., N. meningitidis; E.c., E. coli 
4.11 Cell lines 
Cell adhesion and invasion assays were performed with 
a nasopharyngeal epithelial cell line called Detroit562 
(ATCC® number CCL-138™) [85, 86]. 
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5 Methods 
5.1 Cultivation of bacteria 
E. coli were cultivated overnight at 37 °C on LB agar 
plates in an incubator or in LB media (Table 4.18) at 
200 rpm in an incubator shaker. To select recombinant 
clones, the medium was supplemented with the 
appropriate antibiotic before usage. The antibiotic 
substances and their suitable concentrations are listed in 
Table 4.26. 
N. meningitidis were cultivated overnight at 37 °C with 
5% CO2 on COS or GCB++ agar plates (Table 4.17) in an 
incubator. The selection of recombinant clones occurred 
similar to E. coli by adding antibiotics (Table 4.26) to the 
GCB++ agar plates. For cultivation in liquid culture, the 
bacteria were inoculated into PPM+ (Table 4.13) and 
incubated at 37 °C for the requested period shaking at 
200 rpm in an incubator shaker.  
5.2 Estimating the bacterial cell number by 
determining the optical density at 600nm 
To estimate the number of bacterial cells in a liquid 
culture the optical density at 600 nm (OD600) was 
measured. The bacteria from an agar plate ware 
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inoculated into liquid medium and pre-incubated for 60 
minutes at 37 °C in an incubation shaker. The 
photometer was calibrated with 1 ml of blank medium. 
Afterwards 1 ml of the bacterial suspension was pipetted 
into a cuvette and the absorption at 600 nm was 
measured. An OD600 of 1.0 is equivalent to 
approximately 1x 109 cells/ml of N. meningitidis and 
approximately 2x 108 cells/ml of E. coli. Based on this, 
the number of bacterial cells in the liquid medium was 
calculated or the suspension was adjusted to the 
requested OD600. 
5.3 Preparation of chemically competent 
E.coli cells 
The chemically competent E. coli cells used in this study 
are XL-1 Blue MRF’ and DH5 (Table 4.29). The frozen 
glycerol stocks were streaked on LB agar plates and 
incubated overnight at 37 °C in an incubator. The next 
day one single colony was inoculated into 15 ml of LB 
medium and incubated overnight at 37 °C and 200 rpm 
in an incubator shaker. After incubation 1 ml of starter 
culture was transferred into 25 ml LB medium and 
incubated at 37 °C in a thermoshaker for 1 to 2 h. The 
cells were chilled on ice when the OD600 reached 0.5 to 
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0.7. After 10 to 20 minutes the tubes were centrifuged at 
4 °C for 5 minutes at 4000 rpm, the supernatant was 
decanted, and the pellet was chilled on ice for 1 minute. 
Then the cells were resuspended and washed with 10 ml 
of ice cold 80 mM MgCl2/ 20 mM CaCl2. The suspension 
was centrifuged again at 4 °C for 5 minutes at 4000 rpm, 
the supernatant was decanted and the pellet was 
resuspended in 10 ml of ice cold 80 mM MgCl2/ 
20 mM CaCl2 and chilled on ice for another 30 minutes. 
The cells suspension was centrifuged at 4 °C for 
5 minutes at 4000 rpm and the supernatant was 
decanted. The remaining pellet was resuspended in 800 
µl of 100 mM CaCl2/ 20% glycerol and 100 µl aliquots 
were frozen in liquid nitrogen. The aliquots were stored 
at -80 °C until transformation.  
5.4 Transformation of E. coli 
Chemically competent E. coli strains DH5a and XL-1 
Blue MRF’ were stored in 100 µl aliquots at -80 °C. For 
transformation the aliquots were slowly thawed on ice. 
After the addition of 10 µl plasmid or ligation product the 
bacteria were chilled on ice for another 30 minutes. 
Afterwards the cells were heat shocked at 42 °C for 90 
seconds and immediately cooled down on ice for 
2 minutes. Afterwards 800 µl of SOC medium 
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(Table 4.20) were added and the bacteria were 
incubated at 37 °C for 1 h at 200 rpm in an incubation 
shaker. Finally, the bacteria were streaked on LB agar 
plates and incubated overnight at 37 °C. To ease single 
colony picking 100 µl, 200 µl, and 500 µl of each charge 
were plated separately. If the selection of transformants 
was requested, the LB agar plates were supplemented 
with the appropriate antibiotics (Table 4.26). 
5.5 Transformation of N. meningitidis 
Strains of N. meningitidis were stored at -80 °C in 
freezing medium (Table 4.24). The strain of interest was 
streaked on COS agar plates the day before 
transformation and incubated overnight at 37 °C with 5% 
CO2. After incubation the bacteria were inoculated in 
PPM+ for 1 h at 37 °C at 200 rpm in an incubation 
shaker. After pre-culture, the suspensions were adjusted 
to OD600 = 0.1 in a final volume of 1 ml PPM+. For 
transformation 600 ng to 1 µg of plasmid DNA 
(Chapter 5.7) were added to the suspension and 
incubated for 5 to 6 hours at 37 °C and 200 rpm in an 
incubation shaker. Subsequently, 100 µl of the culture 
were streaked directly on GCB++ agar plates. The 
remaining suspension was centrifuged at 5000 rpm for 
5 minutes at room temperature. The supernatant was 
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discarded, the pellet was resuspended in 100 µl PPM+ 
and the suspension was plated on GCB++ agar plates. 
The plates were incubated overnight at 37 °C with 5% 
CO2. For selection of transformants, the GCB++ agar 
plates were supplemented with the appropriate 
antibiotics (Table 4.26). 
5.6 Preparation of meningococcal genomic 
DNA 
Meningococcal genomic DNA was isolated using the 
QIAamp DNA Mini Kit (Table 4.4) according to the 
manufacturer’s protocol with some modifications. 
Meningococci were streaked on GCB++ agar plates and 
incubated overnight by 37 °C and 5% CO2. The next day, 
colonies were harvested with a cotton swab and 
resuspended in 1.25 ml PBS (Table 4.6). The bacterial 
suspension was centrifuged for 5 minutes at 8000 rpm, 
the supernatant was discarded, and the pellet was 
resuspended in 180 µl ATL buffer (QIAamp DNA Mini 
Kit) with 20 µl Proteinase K (20 mg/ml). Subsequently, 
the suspension was incubated at 56 °C and vortexed 
every 30 minutes for 3 hours. Afterwards, the tube was 
briefly centrifuged and 80 µl RNase A (5 mg/ml) were 
added. After vortexing 10 times, 200 µl AL buffer 
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(QIAamp DNA Mini Kit) were added. Then the tubes 
were vortexed another 10 times and incubated for 
10 minutes at 70 °C. After the addition of 200 µl ethanol 
the tubes were vortexed 10 times and briefly centrifuged. 
The fluid was pipetted onto a QIAamp spin column and 
centrifuged for 1 minute at 8000 rpm. Next, the column 
was transferred into a fresh tube, 500 µl AW1 buffer 
(QIAamp DNA mini kit) were applied and centrifuged for 
1 minute at 8000 rpm. The flow-through was discarded 
and the column was washed with 500 µl AW2 buffer for 
3 minutes at 13000 rpm. Once again, the flow-through 
was discarded. Afterwards, the column was dried via 
1 minute centrifugation at 13000 rpm. Then the column 
was transferred into a fresh 2 ml microcentrifugation 
tube. To elute the DNA, 100 µl 1x TE buffer (QIAamp 
DNA mini kit) was applied to the column and incubated 
at room temperature for 5 minutes. Finally the tube was 
centrifuged for 1 minute at 8000 rpm. The concentration 
and purity of the DNA was measured 
spectrophotometrically. 
5.7 Isolation of plasmid DNA 
Plasmid DNA was isolated using the QIAprep Spin 
Miniprep Kit (Table 4.4). The E. coli strain carrying the 
plasmid of interest was streaked on a selective LB agar 
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plate and incubated overnight at 37 °C. After incubation 
a single colony was picked and inoculated into 5 ml LB 
medium containing the appropriate antibiotic. This 
suspension was incubated overnight at 37 °C and 
200 rpm in an incubation shaker. The next day, the 
culture was centrifuged at 8000 rpm for 5 minutes, the 
supernatant discarded, and the pellet resuspended in 
250 µl P1 buffer (QIAprep Spin Miniprep Kit). The 
suspension was transferred into a 1.5 ml microcentrifuge 
tube, 250 µl P2 buffer (QIAprep Spin Miniprep Kit) were 
added and mixed thoroughly by inverting the tube 4 to 6 
times. After the addition of 350 µl N3 buffer, the fluids 
were mixed immediately by inverting 4 to 6 times. Then 
the tube was centrifuged for 10 minutes at 13000 rpm in 
a microcentrifuge at room temperature. The supernatant 
was transferred into aa QIAprep spin column and 
centrifuged for 30 to 60 seconds at 13000 rpm. After 
discarding the flow-through, the column was washed by 
adding 500 µl PB Buffer (QIAprep Spin Miniprep Kit) and 
centrifuging 30 to 60 seconds at 13000 rpm. The flow-
through was discarded again and the column was 
washed with 750 µl PE buffer (QIAprep Spin Miniprep 
Kit). To remove residual ethanol, the spin column was 
transferred into a fresh tube and centrifuged at full speed 
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for 3 minutes. Finally, the spin column was transferred 
into a fresh microcentrifugation tube and 30 to 50 µl 
ddH2O were added. After incubating for 5 minutes at 
room temperature, the tube was centrifuged for 
2 minutes at 13000 rpm. The concentration and purity of 
the DNA was measured spectrophotometrically. 
5.8 Preparation of bacterial lysates for 
colony PCR 
To obtain bacterial lysates, a single colony was 
inoculated into 20 to 30 µl 1x PBS (Table 4.6). The 
suspension was incubated for 5 (E. coli) or 15 
(N. meningitidis) minutes at 100 °C in a heating block 
and then immediately cooled down on ice for 5 minutes. 
After centrifuging 1 minute at 13000 rpm, the 
supernatant was discarded, and the pellet was 
resuspended in 30 µl 1x PBS. Bacterial lysates were 
used for quick PCR checks in transformation 
procedures. One µl per 25 µl PCR formulation was used. 
5.9 Polymerase chain reaction (PCR) 
Polymerase chain reactions were used to amplify 
specific DNA fragments. For cloning purposes Q5® 
High-Fidelity DNA polymerase was used because of its 
proof-reading activity. To screen colonies in 
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transformation procedures or to verify genomic 
alterations, Taq DNA polymerase was utilized. 
Generally, 100 ng of template DNA was used. To screen 
for transformants, 1 µl bacterial lysate or a colony was 
used as template. PCRs were generally prepared on ice 
and quickly transferred into a preheated thermocycler. 
To recognize DNA contamination, each PCR was done 
with a negative control without DNA template. The 
expected size of the PCR product was calculated by in 
silico genome analyses using Artemis (Table 5.10). 
PCRs using Taq polymerase were performed in 
modification of the manufacturer’s protocol as given in 
Table 5.1. 
Table 5.1 PCR protocol for Taq DNA polymerase 
Ingredient 
25 µl 
reaction 
Final 
Concentration 
10x ThermoPol reaction buffer 2.5 µl 1x 
20 mM dNTPs 0.25 µl 200 µM 
25 µM forward primer 0.5 µl 0.5 µM 
25 µM reverse primer 0.5 µl 0.5 µM 
Template DNA Variable <1 µg 
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Ingredient 
25 µl 
reaction 
Final 
Concentration 
Taq DNA polymerase 0.25 µl 0.05 U/µl 
ddH2O ad 25 µl  
 
The standard PCR program for PCRs using Taq 
polymerase is given in Table 5.2.  
Table 5.2 Thermocycling program for Taq DNA 
polymerase 
Step Temperature Time 
1. Initial denaturation 95 °C 
30 seconds 
(5 minutes for 
lysates) 
2. Denaturation 95 °C 30 seconds 
3. Annealing (Ta) 50-65 °C 30 seconds 
4. Extension 68 °C 1 minute/kb 
5. Step 2 to 4 repeated 
    25 to 35 times 
  
6. Final extension 68 °C 5 minutes 
7. Hold 4 °C ∞ 
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The melting temperatures (Tm) of each primer were 
estimated with the following formula. 
𝑇𝑚 = 2 ∗  (𝐴 + 𝑇) + 4 ∗  (𝐺 +  𝐶) 
Using Taq polymerase, the annealing temperature (Ta) 
was obtained by subtracting 5 °C from the melting 
temperatures (Tm). The following Table 5.3 shows the 
standard protocol for PCRs utilizing the Q5® High-
Fidelity DNA polymerase. 
Table 5.3 PCR protocol for Q5® High-Fidelity DNA 
polymerase 
Ingredient 
50 µl 
reaction 
Final 
Concentration 
5x Q5 reaction buffer 10 µl 1x 
20 mM dNTPs 0.5 µl 200 µM 
25 µM forward primer 1 µl 0.5 µM 
25 µM reverse primer 1 µl 0.5 µM 
Template DNA variable <1 µg 
Q5® High-Fidelity DNA 
polymerase 
0.5 µl 0.02 U/µl 
ddH2O ad 50 µl  
 
Methods 
 
83 
The standard PCR program for PCRs using the Q5® 
High-Fidelity DNA polymerase is given in Table 5.4. 
Table 5.4 Thermocycling program for Q5® High-Fidelity 
DNA polymerase 
Step Temperature Time 
1. Initial denaturation 98 °C 30 seconds 
2. Denaturation 98 °C 10 seconds 
3. Annealing (Ta) 50-72 °C 30 seconds 
4. Extension 72 °C 
20-30 
seconds/kb 
5. Step 2 to 4 repeated  
    25 to 35 times 
  
6. Final extension 72 °C 2 minutes 
7. Hold 4 °C ∞ 
 
Applying the Q5® High-Fidelity DNA polymerase the 
annealing temperature (Ta) was calculated using the 
NEB Tm Calculator (http://tmcalculator.neb.com/#!/). 
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5.10 Major PCRs 
The following Table 5.5 lists major PCRs performed in 
this study. The primers (see Table 4.27) are listed next 
to a short description, elongation time, annealing 
temperature and the used polymerase.  
Table 5.5 Major PCRs performed in this study 
Primer 
1a 
Primer 
2a 
Description and 
Usage 
ETb 
(s) 
ATc PMd 
1110 1111 8013 cas9 
complementation 
30 55 °C Q5 
1122 1123 8013 cas9 
complementation 
verification 
120 56 °C Taq 
976 1122 8013 cas9 
complementation 
verification 
300 56 °C Taq 
977 1123 8013 cas9 
complementation 
verification 
300 56°C Taq 
10511 10512 8013 cas9 knockout 20 50 °C Q5 
903 904 8013 cas9 knockout 
verification 
300 60 °C Taq 
328 904 8013 cas9 knockout 
verification 
40 55 °C Taq 
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Primer 
1a 
Primer 
2a 
Description and 
Usage 
ETb 
(s) 
ATc PMd 
329 903 8013 cas9 knockout 
verification 
40 55 °C Taq 
1045 1046 8013 CRISPR 
complementation 
40 59 °C Q5 
974 975 8013 CRISPR  
knock-in verification/ 
knockout exclusion 
40 64 °C Taq 
11443 11115 8013 CRISPR  
knockout 
10 63 °C Q5 
11444 11116 8013 CRISPR  
knockout 
10 63 °C Q5 
1031 1032 8013 CRISPR  
knockout verification 
210 60 °C Taq 
328 1031 8013 CRISPR  
knockout verification 
40 55 °C Taq 
329 1032 8013 CRISPR  
knockout verification 
40 55 °C Taq 
329 11444 8013 CRISPR  
knockout verification/ 
knockout vector check 
40 50 °C Taq 
328 11443 8013 CRISPR  
knockout verification/ 
knockout vector check 
40 50 °C Taq 
1043 1044 8013 rnc 
complementation 
20 53 °C Q5 
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Primer 
1a 
Primer 
2a 
Description and 
Usage 
ETb 
(s) 
ATc PMd 
971 1049 8013 rnc 
complementation 
verification 
180 65 °C Taq 
971 988 8013 rnc 
complementation 
verification 
180 65 °C Taq 
970 989 8013 rnc 
complementation 
verification 
180 65 °C Taq 
1047 1048 8013 tracrRNA 
complementation 
20 53 °C Q5 
1049 989 8013 tracrRNA 
complementation 
verification 
180 65 °C Taq 
1048 988 8013 tracrRNA 
complementation 
verification 
180 65 °C Taq 
1047 989 8013 tracrRNA 
complementation 
verification 
180 65 °C Taq 
833 729 8013 tracrRNA  
knockout 
20 56 °C Q5 
834 835 8013 tracrRNA  
knockout 
20 56 °C Q5 
903 328 8013 tracrRNA  
knockout verification 
60 50 °C Taq 
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Primer 
1a 
Primer 
2a 
Description and 
Usage 
ETb 
(s) 
ATc PMd 
988 989 8013 tracrRNA/ rnc 
knockout verification 
240 60 °C Taq 
903 739 8013 tracrRNA  
knockout verification 
210 60 °C Taq 
976 977 8013/ WUE2594 cas9 
knock-in verification/ 
knockout exclusion 
40 60 °C Taq 
970 971 8013/ WUE2594 rnc 
knock-in verification/ 
knockout exclusion 
40 64 °C Taq 
10509 10510 8013/ WUE2594 cas9 
knockout 
20 50 °C Q5 
552 554 8013/ WUE2594 rnc 
knockout 
20 55 °C Q5 
550 551 8013/ WUE2594 rnc 
knockout 
20 55 °C Q5 
617 618 8013/ WUE2594 rnc 
knockout verification 
210 60 °C Taq 
317 329 8013/ WUE2594 rnc 
knockout verification 
60 50 °C Taq 
618 328 8013/ WUE2594 rnc 
knockout verification 
60 50 °C Taq 
739 329 8013/ WUE2594 
tracrRNA knockout 
verification 
60 50 °C Taq 
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Primer 
1a 
Primer 
2a 
Description and 
Usage 
ETb 
(s) 
ATc PMd 
723 733 WUE2594 tracrRNA 
knockout 
20 55 °C Q5 
729 730 WUE2594 tracrRNA 
knockout 
20 55 °C Q5 
740 328 WUE2594 tracrRNA 
knockout verification 
60 50 °C Taq 
739 740 WUE2594 tracrRNA 
knockout verification 
210 60 °C Taq 
10515 10516 WUE2594 cas9  
knockout 
20 50 °C Q5 
905 906 WUE2594 cas9  
knockout verification 
300 60 °C Taq 
328 906 WUE2594 cas9  
knockout verification 
40 50 °C Taq 
329 905 WUE2594 cas9  
knockout verification 
40 50 °C Taq 
11116 11306 WUE2594 CRISPR 
knockout 
20 60 °C Q5 
11114 11115 WUE2594 CRISPR 
knockout 
20 60 °C Q5 
11604 11605 WUE2594 CRISPR 
knockout verification 
210 60 °C Taq 
328 11605 WUE2594 CRISPR 
knockout verification 
40 55 °C Taq 
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Primer 
1a 
Primer 
2a 
Description and 
Usage 
ETb 
(s) 
ATc PMd 
329 11604 WUE2594 CRISPR 
knockout verification/ 
knockout vector check 
40 55 °C Taq 
972 973 WUE2594 CRISPR 
knock-in verification/ 
knockout exclusion 
40 64 °C Taq 
243 1049 pCompInd integration 
control 
150 50 °C Taq 
1035 1118 pAH-5 construction 60 55 °C Q5 
1117 1118 pAH-4 construction 60 55 °C Q5 
1054 1055 pAH-4/ pAH-5 control 210 58 °C Taq 
12662 12663 pGCC2 cas9-comp 100 52°C Q5 
1227 1228 8013 cas9 probe  8 55°C Q5 
1229 1230 8013 NMV0031 probe 8 55°C Q5 
243 242 pBluescript II –SK 
integration control 
180 58°C Taq 
 
aID-number 0-9999 according to the AG SCHOEN oligonucleotide 
collection, 10000-99999 according to the common IMIB 
oligonucleotide collection 
b elongation time 
c annealing temperature (Ta) 
d utilized polymerase: ‘Q5’ for Q5® High-Fidelity DNA polymerase, 
‘Taq’ for Taq polymerase 
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PCR analysis of mutant strains were always performed 
according to the same principle. Primers located outside 
of the region used for recombination and outward facing 
primers located on the resistance gene were combined 
as depicted in Figure 5.1. 
 
Figure 5.1 Schematic representation of PCRs used for 
mutant verification 
Schematic representation of the replacement (A) and 
complementation (B) of a fictional gene called genX via 
homologous recombination. The homologous regions 
upstream (HRU) and downstream (HRD) of genX are 
identical in the genome and on the knockout vector. To 
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verify recombinant strains by PCR primers located 
outside of the region used for recombination (Out1 and 
Out2) and outward facing primers located on the 
resistance gene respectively the gene to be 
complemented (In1 and In2) were combined. The 
combination of Out1 and Out2 amplifies the whole 
region of recombination and this way detects double 
cross-over mutants. The combinations Out1 x In1 and 
Out2 x In2 additionally allow to determine the 
orientation of the resistance cassette.  
5.11 Sequencing PCR products and plasmids  
Sequencing was done by GATC (Köln DE). Therefore, 
sequencing reactions were prepared with 1 µl of the 
respective primer (25 µM) and 20 – 80 ng of PCR 
fragments or 200 – 400 ng of plasmid DNA in a 1.5 ml 
tube with a final volume of 10 µl in ddH2O. 
5.12 DNA digestion 
The digestion of DNA fragments, plasmid DNA or 
genomic DNA was performed by using restriction 
endonucleases. Table 5.6 lists the protocol for general 
restriction digests. The suitable buffer was chosen 
according to the ‘NEBuffer Activity/Performance Chart 
with Restriction Enzymes’ provided by New England 
Biolabs (https://www.neb.com/tools-and-
resources/usage-guidelines/nebuffer-performance-chart-
with-restriction-enzymes). If two restriction enzymes 
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were used simultaneously, the buffer was chosen with 
New England Biolabs’ ‘Double Digest Finder’ 
(https://www.neb.com/tools-and-resources/interactive-
tools/double-digest-finder). 
Table 5.6 Standard restriction digest protocol 
Ingredient  50 µl reaction 
Restriction enzyme  10 U 
DNA  1 µg 
10x NEB Buffer  5 µl 
ddH2O  ad 50 µl 
Incubation time  1-2 h 
Incubation temperature  37 °C 
 
Digested DNA fragments were purified using the MSB 
Spin PCRapace Kit (Table 4.4). Digested plasmid DNA 
was separated electrophoretically and the fragments of 
requested size were extracted from the gel using the 
Invisorb Spin DNA Extraction Kit.  
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5.13 Agarose gel electrophoresis of DNA 
To visualise PCR products, agarose gel electrophoreses 
were performed. The PCR products were separated 
electrophoretically by size in an agarose gel with TAE 
buffer. This way it was possible to estimate the length of 
PCR products. 
Depending on the size of the expected PCR product, 
agarose was added to 1x TAE buffer at a concentration 
of 1% or 2% (w/v). The agarose suspension was heated 
in a microwave and cooled down while permanently 
stirred. The hand-warm agarose solution was poured 
into a gel tray with the well comb in place. As standard 
molecular weight marker 5 µl ‘Hyper Ladder I’ 
(New England Biolabs, Frankfurt) was used. To each 
PCR product sample 6x DNA loading buffer (Table 4.8) 
was added to a 1x concentration and pipetted into a gel 
pocket. DNA samples were separated for approximately 
1 h at 170 V in 1x TAE buffer. The gels were stained in 
GelRed™ (Biotium, Fremont US) bath for 45 minutes 
afterwards. To visualize the bands of the DNA fragments 
via UV light at 302 nm or 312 nm the Chemi Doc MP 
System was used. Depending on the intended use, the 
PCR products were either purified or extracted from the 
gel. For sequencing or cloning purposes, only 3 µl of 
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each PCR reaction were used for electrophoretic 
separation. The remaining quantity was purified using 
the MSB Spin PCRapace Kit (Table 4.4). To separate 
fragments after digestion, the DNA of requested size 
was extracted from the gel using the Invisorb Spin DNA 
Extraction Kit (Table 4.4). 
5.14 Purification of DNA fragments 
To purify DNA fragments, the MSB Spin PCRapace Kit 
(Table 4.4) was used following the manufacturers 
description. First, 50 µl PCR-mixture were very well 
mixed with 250 µl Binding Buffer to ease the binding of 
DNA fragments to the silica membrane of the spin filter. 
Afterwards the sample was transferred onto the spin 
filter, incubated for 1 minute at room temperature and 
centrifuged for 4 minutes at maximum speed to remove 
contaminants. Impurities and detergents do not bind to 
the silica membrane and are therefore drawn through the 
column. Then, the spin filter was transferred into a new 
1.5 ml receiver tube and 10 μl Elution Buffer were added. 
Subsequently, the sample was incubated for 1 minute at 
room temperature and centrifuged for 1 minute at 
11000 rpm. The gathered samples were stored at 4°C. 
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5.15 Gel Extraction 
To extract electrophoretically separated DNA from a 
agarose gel, the Invisorb Spin DNA Extraction Kit 
(Table 4.4) following the manufacturer’s protocol. The 
bands of interest were cut and the gel slices were 
transferred into a 1.5 ml microcentrifugation tube. To gel 
slices up to 150 mg 500 µl Gel Solubilizer was added 
and 1 ml to gel slices up to 300 mg. The kit was not 
suitable for slices heavier than 300 mg. The tubes were 
incubated at 50 °C for 10 minutes until the gel was 
completely solubilized. Afterwards, 250 µl Binding 
Enhancer were added to 500 µl reaction volume, and 
500 µl to 1 ml reaction volume respectively, and mixed 
thoroughly by pipetting up and down. Then 800 µl of the 
sample were transferred onto the spin filter and 
centrifuged at 11000 rpm for 2 minutes. After discarding 
the filtrate the residual sample volume was loaded and 
centrifuged the same way. To purify the extracted DNA 
the spin filter was washed twice by adding 500 µl 
Washing buffer and centrifuging for 1 minute at 
11000 rpm. Subsequently, the residual ethanol was 
removed by centrifuging for 4 minutes at 13000 rpm. The 
spin filter was transferred into a new 1.5 ml receiver tube 
and 15 µl Elution Buffer were added directly onto the 
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centre of the spin filter. After incubating at room 
temperature for 1 minute, the tubes were centrifuged for 
1 minute at 11000 rpm. The purity and concentration of 
the extracted DNA was measured 
spectrophotometrically.  
5.16 DNA ligation 
A ligation of purified digested DNA fragments and the 
linearized vector was performed by using the T4 DNA 
ligase. Generally, a molar ratio of 1:3 vector to insert was 
used in standard ligation reaction. The proportion of 
insert to the vector was calculated with the following 
formula. 
𝑚 (𝑖𝑛𝑠𝑒𝑟𝑡)[𝑛𝑔] =
𝑛 (𝑖𝑛𝑠𝑒𝑟𝑡)
𝑛 (𝑣𝑒𝑐𝑡𝑜𝑟)
∗ 𝑚 (𝑣𝑒𝑐𝑡𝑜𝑟) [𝑛𝑔] ∗
𝑙 (𝑖𝑛𝑠𝑒𝑟𝑡) [𝑏𝑝]
𝑙 (𝑣𝑒𝑐𝑡𝑜𝑟)[𝑏𝑝]
   
Ligations were generally prepared in microcentrifuge 
tubes on ice and quickly transferred in a thermocycler 
precooled to 16 °C. The following Table 5.7 shows the 
standard ligation protocol using the T4 DNA ligase.  
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Table 5.7 Standard ligation protocol using T4 DNA 
ligase 
Ingredient  20 µl reaction 
10x T4 DNA Ligase buffer  2 µl 
Vector DNA  50 ng 
Insert DNA  Variable 
T4 DNA Ligase  1 µl 
ddH2O  ad 20 µl 
 
The ligation buffer was thawed and resuspended at room 
temperature. After incubating overnight at 16 °C the 
ligation was heat inactivated at 65 °C for 10 minutes and 
chilled on ice. Afterwards the ligation product was used 
for chemical transformation or stored at -20 °C.  
5.17 Mutant construction 
In general deletion mutants were generated replacing 
the respective gene with a kanamycin resistance 
cassette. Approximately 600 bp upstream and 
downstream of the target gene were amplified with 
oligonucleotides modified to introduce different enzyme 
restriction sites (Table 4.27). The fragments were 
digested, purified and cloned into the pBluescript II -SK 
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vector along with the digested kanamycin resistance 
cassette. The obtained knockout plasmids contained a 
kanamycin resistance cassette flanked by the upstream 
and downstream region of the respective gene. The 
meningococcal strains 8013 and WUE2594 were 
transformed with the linearized plasmids and thus 
homologous recombination resulted in a replacement of 
the target gene. Using linear fragments reduces the 
amount of transformed cells but increases the chance of 
double crossover mutants [87]. The correct insertion of 
the resistance gene was confirmed by PCR, sequencing 
and Southern blot analysis. In this study, knockout 
mutants of cas9, rnc, CRISPR and tracrRNA in 8013 as 
well as WUE2594 were generated. To verify the 
obtained results the transformation was repeated to 
obtain multiple biological replicates (see Table 4.29 and 
Figure 6.1 for detailed information).  
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Table 5.8 lists the gene loci of the CRISPR/Cas system 
genes.  
Table 5.8 CRISPR/Cas system gene loci 
Gene Protein 8013 WUE2594 
Locus St.a Locus St.a 
cas1 Cas1 1920388 to 
1921302 
+ 
376943 to 
376020 
- 
cas2 Cas2 1921295 to 
1921621 
+ 
374160 to 
375646 
- 
cas9 Cas9 1917073 to 
1920321 
+ 
377010 to 
380258 
- 
rnc RNase III 1660804 to 
1661523 
- 
631217 to 
632149 
+ 
tracrRNA  1916858 to 
1916964 
- 
380367 to 
380473 
+ 
CRISPR  1921685 to 
1923370 
- 
374160 to 
375646 
+ 
scaRNA  1923335 to 
1923358 
+ 
374172 to 
374195 
- 
 
a Strand: + leading strand / - lagging strand 
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Figure 5.2 Mutant construction in 8013 and WUE2594 
Depicted are the CRISPR/Cas loci in 8013 (A) and 
WUE2594 (B) and the rnc loci in 8013 (C) and 
WUE2594 (D) as well as the linearized knockout 
plasmids aligned to their point of integration. The scale 
in bp above the genes denotes the place in the genome 
according to the published genome sequences. Bold 
white arrows indicate genes and their reading direction, 
gene fragments are indicated by white boxes. Promotors 
were predicted by BPROM (Table 5.10) and are 
depicted as small angled arrows. Terminators were 
predicted by FindTerm (Table 5.10) and are depicted as 
loops. Loci of non-coding RNAs are indicated by white 
boxes with angled arrows. Black boxes indicate non-
neisserial DNA, in particular kanamycin-resistance 
cassettes. Vertical lines indicate CRISPR Spacer.  
Arrows below and above indicate the binding sites of 
primers used for mutant verification, primer numbers are 
given next to the arrows. Drawn to scale. 
5.18 Complementant construction 
To complement the knockout mutants, copies of the 
knocked-out genes were inserted into the chromosomal 
DNA. The requested gene was amplified from wild type 
DNA with oligonucleotides modified to introduce enzyme 
restriction sites. The complementation plasmids were 
digested, and the amplified gene fragment was 
integrated into the multiple cloning sites. Subsequently 
the gene was integrated by homologous recombination. 
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Copies of cas9 were inserted in a locus between lctP 
and aspC, copies of tracrRNA and rnc in a locus 
between porA and NMV0959. Figure 5.3 shows the 
integration sites. The strains 8013∆cas9::Kmr, 
8013∆rnc::Kmr and 8013∆tracrRNA::Kmr were 
complemented with their respective knocked-out gene. 
In addition, 8013∆tracrRNA::Kmr was complemented 
with a cas9 copy to examine possible cis-effects of the 
tracrRNA knockout on cas9 expression. Maybe due to 
the high amount of repeats in the CRISPR array, it was 
not possible to generate an complementant for 
8013∆CRISPR::Kmr. The WUE2594 mutants were not 
complemented. Figure 6.1 shows relations of the 
mutants and complementants, as well as the utilized 
plasmids in detail. The correct insertion was confirmed 
by PCR and Southern blot analysis.  
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Figure 5.3 Complementant construction in 8013 
Complementant construction using pCompInd (A) and 
pGCC2 (B). Schematic elements are used as described 
in Figure 5.1. Restriction sites of unknown sequence 
and estimated position are marked with p*. Drawn to 
scale. 
Methods 
 
 
106 
5.19 Generation of DIG-labelled DNA probes 
DIG-labelled DNA probes are needed for Southern Blots. 
The requested DNA fragment was amplified using the 
Q5® High-Fidelity DNA Polymerase, purified in the prior 
described manner and eluted in 30 µl ddH2O. 
Subsequently, 15 µl of the DNA were denatured in a 
heating block at 95 °C for 10 minutes and then 
immediately cooled down on ice. Then, 2 µl 
10x hexanucleotide mix (Table 4.2), 2 µl 10x DIG DNA 
labelling mix (Table 4.2) and 1 µl Klenow enzyme 
(Table 4.5) were added. The labelling reaction was 
mixed thoroughly and incubated overnight at 37 °C. The 
reaction was stopped by adding 2 µl of 0.2 M EDTA. To 
precipitate the DNA 2.5 µl of 3 M sodium acetate and 
75 µl ice cold 96% ethanol were added and cooled 
at -80 °C for 30 minutes. After centrifuging for 
15 minutes at 13000 rpm and 4 °C, the supernatant was 
discarded and the pellet was washed with 1000 µl ice 
cold 70% ethanol. The ethanol was removed carefully by 
centrifuging for 15 minutes at 13000 rpm and 4 °C and 
discarding the supernatant. The pellet was dried via 
vacuum centrifugation for 5 minutes at medium heat. 
Finally, the probe was resuspended in 50 µl 1x TE 
buffer. 
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To quantify the DNA via dot blot, 1 µl of serially diluted 
DIG-labelled DNA and a DIG-labelled control DNA were 
pipetted onto a nylon membrane. The DNA was cross 
linked with an UV cross linker (Table 4.1) for 1 minute. 
Afterwards, the probes were detected by 
chemiluminescence  with the ChemiDoc MP system and 
the concentration was estimated by comparison to the 
control DNA of known concentration. 
5.20 Southern Blot 
One microgram genomic DNA was digested overnight at 
37 °C with a suitable restriction enzyme in a 30 µl 
reaction volume. The digested DNA and the DIG-labelled 
molecular weight marker were loaded into a 0.8% 
agarose gel and electrophoretically separated at 80 V for 
5-6 hours. To depurinate, the gel was incubated in 
0.25 M HCl for 20 minutes. Afterwards, it was denatured 
in 5 M NaOH/ 1.5 M NaCl for 30 minutes and neutralized 
in 5 M TRIS, pH 7.5/ 1.5 M NaCl for another 30 minutes. 
The blotting sandwich was built up and the flow of 20x 
SSC buffer (Table 4.9) transferred the negatively 
charged DNA from the agarose gel to the positively 
charged nylon membrane overnight. The next day, the 
nylon membrane was dried and cross linked in an UV 
crosslinker for 1 minute. The membrane was pre-
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hybridized for 30 minutes in 50 ml high SDS 
hybridisation buffer (Table 4.9) at 48 °C. In the 
meantime, 500 ng of the DIG-labelled DNA probe was 
added to 50 ml of high SDS hybridisation buffer, boiled in 
a water bath for 10 minutes and immediately cooled 
down on ice for 10 minutes. The pre-hybridisation buffer 
(Table 4.9) was discarded and the membrane was 
incubated at 48 °C overnight in the DIG-labelled probe.  
5.21 Detection of DIG-labelled DNA by 
chemiluminescence  
For the detection of hybridized DIG-labelled DNA, the 
membrane was washed twice in stringent 
washing buffer I (Table 4.9) at room temperature for 
5 minutes, and twice in stringent washing buffer II 
(Table 4.9) at 68 °C for 15 minutes. The following steps 
were performed at room temperature on a laboratory 
shaker. First, the membrane was incubated in 
1x washing buffer (Table 4.9) for 5 minutes, then in 1x 
blocking solution (Table 4.9) for 30 minutes and finally in 
antibody solution for another 30 minutes. Afterwards the 
membrane was washed twice for 15 minutes in 1x 
washing buffer and incubated in detection buffer 
(Table 4.9) for 5 minutes. Finally, CSDP working solution 
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(Table 4.9) was pipetted onto the membrane. After 
5 minutes the membrane was wrapped into a cling film 
and incubated at 37 °C for 15 minutes. The membrane 
was developed with the ChemiDoc MP System 
according to the manufacturer’s instructions. 
5.22 SDS-PAGE 
For the preparation of SDS-polyacrylamide gels the 
12.5% separating gel solution (Table 4.10) was mixed 
thoroughly and pipetted into the casting frame. To obtain 
horizontal separating gel, water was filled into the 
casting frame on top of the SDS-polyacrylamide gel. 
After 30 minutes the water was discarded and the 
loading gel (Table 4.10) was pipetted into the frame. A 
comb was inserted without trapping air under its teeth. 
After 1 hour, the gel was either used immediately or 
stored at 4 °C until usage. Before gel electrophoresis, 
protein samples were incubated at 95 °C for 10 minutes 
and immediately cooled on ice. The 12.5% SDS-
polyacrylamide gels were loaded with 10 – 20 µl protein 
sample and 5 µl prestained protein marker (Table 4.3). 
The proteins were separated at 160 V for approximately 
1.5 hours in electrophoresis buffer (Table 4.10). 
Subsequently, the gel was fixed in fixing solution for 
30-60 minutes. Afterwards, it was transferred into 
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Coomassie staining solution (Table 4.10) and incubated 
until the desired band intensity was reached. To destain 
the gel it was bathed in 10% acetic acid for 2 hours or 
more.  
5.23 In vitro growth experiments with 
N.meningitidis 
The strains were grown overnight at 37 °C/ 5% CO2 on 
COS agar plates. The next day, the mutants and the 
corresponding wild type were inoculated into the medium 
of interest. The cultures were incubated at 37 °C and 
200 rpm for 1 hour. Afterwards, the meningococci were 
adjusted to an OD600 of 0.1 and further incubated at 
37 °C and 200 rpm. Growth was determined by 
measuring the OD600 every hour.  
5.24 Serial dilution 
Serial dilutions were used to reduce the number of 
bacteria to a countable level when plated. One hundred 
millilitre of 1 ml bacterial suspension were transferred 
into 900 µl 1x PBS and mixed thoroughly to reduce the 
plated number of colony-forming units (CFU) by 10-1. 
Subsequently, 100 µl of the 10-1 dilution were transferred 
into 900 µl sterile 1x PBS to reduce the plated CFU 
another time by 10-1. After mixing thoroughly this step 
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was repeated until an estimated scale of 102 to 103 was 
reached. Three stages of the dilution series were plated 
in triplicates. The mean CFU of each dilution step was 
determined and multiplied by the cumulative dilution 
factor. 
5.25 Cell adhesion and invasion assay 
Cell adhesion and invasion assays were performed on 
Detroit562 nasopharyngeal epithelial cells 
(Chapter 4.11). Detroit562 cells double cell number 
within a day so 1x 105 cells per well were seeded two 
days in advance into a 24-well plate to obtain 4x 105 for 
experiment. The wild type strain and the respective 
mutant strains were streaked out on COS blood agar 
plates overnight at 37 °C/ 5% CO2. The next day the 
bacteria were inoculated into 5 ml preculture medium 
(Table 5.9) and cultured for 1 hour at 37 °C and 200 rpm 
in an incubation shaker. In the meantime, the Detroit562 
cells were washed twice with 1 ml cell culture medium 
(Table 5.9) to remove non-adherent cells. After that, 1 ml 
infection medium (Table 5.9) was added to each well 
and the viability and confluence was checked with a 
microscope. After incubating, the number of bacterial 
cells was estimated by measuring the OD600 and the 
Detroit562 cells were infected with a predetermined 
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multiplicity of bacteria (‘multiplicity of infection’ see 
Table 5.9). Subsequently, the 24 well plate was 
incubated for 4 hours at 37 °C with 5% CO2. In the 
meantime, the number of seeded bacteria was 
determined by adding the same infection volume to 1 ml 
1x PBS and plating serial dilutions in triplicates. Four 
hours post infection, CFU in the supernatant was 
determined the same way. The supernatant was 
removed carefully, and the cells were washed with 1 ml 
infection medium. Four wells per strain were used to 
determine the ‘invasive’ or ‘gentamicin protected’ 
bacteria and treated with 0.2 mg/ml gentamicin for 1 
hour at 37 °C to kill the extracellular bacteria. Another 4 
wells per strain were used to assess the ‘adherent’ or 
‘cell associated’ bacteria and treated with 1% saponin for 
15 minutes to break up the Detroit562 cells. The CFU of 
the ‘adherent’ bacteria were determined by plating the 
serial dilution in triplicates. One hour post gentamicin 
treatment the ‘invasive’ bacteria were determined the 
same way. The next day, the CFU was determined via 
colony counter and the ‘adherent’ bacteria were 
compared to the ‘seeded’ bacteria. Likewise, the 
‘invasive’ bacteria were compared to the ‘adherent’ 
bacteria. 
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Table 5.9 Specifications of the adhesion and invasion 
assay for 8013 and WUE2594 strains 
 WUE2594 8013 
Preculture medium 
GCBL++ 
(Table 4.16) 
EMEM+++ 
(Table 4.22) 
Cell culture medium  EMEM+++ EMEM+++ 
Infection medium  
RPMI+ 
(Table 4.25) 
EMEM+++ 
Multiplicity of infection 
(MOI) 
10 20 
 
5.26 Static biofilm assay for N. meningitides 
The requested strains were grown at 37 °C/ 5% CO2 on 
COS agar plates for 8 hours. After incubation the 
meningococci were resuspended in the medium of 
interest and adjusted to an OD600 of 0.1. One hundred 
microliter bacterial suspension were seeded per well of a 
96-well microtiter plate and incubated at 37 °C, 5% CO2 
overnight. After 16 hours of incubation the supernatant 
was removed, and the adherent bacteria were stained by 
adding 100 µl 0.05% crystal violet for 10 minutes at room 
temperature. The wells were washed twice with 200 µl 
PBS per well. Subsequently, the remaining crystal violet 
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stain of the biofilm was dissolved with 100 µl 96% 
ethanol per well and incubated at room temperature for 
20 minutes. Finally, the optical density at 595 nm (OD595) 
was measured for each well in a spectrometer. 
5.27 Computational analyses 
The following Table 5.10 lists the software and 
computational tools utilized for this study. The Basic 
Local Alignment Search Tool of the National Center of 
Biotechnology Information (NCBI BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used for 
similarity searches against nucleotide databases.  
Table 5.10 Utilized software 
Program Application 
Developer/ 
Source 
Excel 2016 
Statistics and spreadsheet 
analysis 
Microsoft  
SnapGene 2.8  Plasmid construction GSL Biotech LLC 
Serial Cloner 
2.6  
DNA sequence analysis Serial Basic 
BioEdit 7.2.5 
Sequence alignment and 
analysis 
Ibis Bioscience [88] 
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Program Application 
Developer/ 
Source 
Blast 2.8.1+ 
Sequence alignment and 
comparison  
National Center for 
biotechnology 
Information (NCBI) 
[89, 90] 
Gimp 2.8.20 
Creating graphical figures or 
illustrations 
S. Kimball, P. 
Mattis 
(GPLv3+) 
Image Lab 5.2 
Software for ChemiDoc MP 
Imaging System 
Bio-Rad, Hercules 
US 
Artemis 16.0.0 Genome browsing 
Wellcome Trust 
Sanger Institute 
[91] 
NeMeSys Neisseria genome browsing [47] 
BPROM Promotor prediction Softberry [92] 
FindTerm Terminator prediction Softberry [92] 
ACT 13.0.0 
Pairwise comparison of two 
or more DNA sequences 
Wellcome Trust 
Sanger Institute 
[93] 
PowerPoint 
2016 
Creating graphical figures or 
illustrations 
Microsoft 
Word 2016 Textwork Microsoft 
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6 Results 
6.1 Verification of 8013 and WUE2594 
mutant strains 
In order to analyse the influence of the CRISPR/Cas 
system experimentally, knockout mutants of cas9, rnc, 
tracrRNA, and the CRISPR-array were constructed in 
the genetic background of N. meningitidis strain 8013 
and WUE2594. 
The knockout mutants were generated by replacing the 
entire coding sequence with a kanamycin resistance 
cassette (see 5.17). The deletion of the tracrRNA, rnc 
and, CRISPR in 8013 was performed twice and the 
deletion of cas9 in 8013 was done three times in order to 
gain multiple biological replicates (see Figure 6.1). The 
8013 cas9, rnc, and tracrRNA knockout strains were 
complemented by inserting a copy of the respective wild 
type gene along with their promotor region into the porA 
locus using the integration plasmid pCompInd or into the 
lctP-aspC locus using pGCC2. In order to analyse 
potential polar effects of the tracrRNA knockout on the 
expression of cas9, a second copy of cas9 was 
integrated in the genome of an 8013 tracrRNA knockout 
strain (see Chapter 5.18). 
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Figure 6.1 Genealogy of 8013 mutant strains used in 
this study 
This flowchart depicts the wild type strain and the 
respective mutants of strain 8013. Boxes in dark grey 
indicate biological replicates of transformed strains. The 
bold text provides a short description of the genotype. 
The names are given below according to the 
AG SCHOEN strain list. Arrows indicate transformations 
with the utilized plasmid in boxes with blunt edges.  
 
The correct insertion of the resistance cassette in 
WUE2594 and 8013 mutant strains was confirmed by 
southern blot analysis (Figure 6.2, Figure 6.3, and Figure 
6.4), RT-PCR (Figure 6.5), and PCR (Figure 6.6 A+B). 
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Figure 6.2 Southern blot analysis of WUE2594 knockout 
mutants  
Southern blot analysis to verify the genotypes of 
WUE2594Δcas9::Kmr, WUE2594Δrnc::Kmr, 
WUE2594ΔtracrRNA::Kmr and WUE2594ΔCRISPR::Kmr. 
The genomic DNA of the mutant and the wild type 
strains were digested simultaneously with ClaI and 
HindIII and used for Southern blot hybridisation with the 
kanamycin resistance gene as probe. On the right side 
is the DNA Molecular Weight Marker VII, DIG-labelled 
(M), labelled with the band size in bp. The sizes of the 
expected fragments and the location of ClaI and HindIII 
restriction sites in the genome are given schematically 
in Figure 6.3.  
M 
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A
 
B
 
C
 
D
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Figure 6.3 Computationally predicted fragment sizes of 
WUE2594 mutant strains in Southern blot with Tn903-
probe after HindIII/ClaI double digest 
Depicted are the CRISPR/Cas loci of 
WUE2594Δcas9::Kmr (A), WUE2594ΔtracrRNA::Kmr (B) 
and WUE2594ΔCRISPR::Kmr (C) and the 
WUE2594Δrnc::Kmr rnc locus (D). The scale in bp 
above the genes denotes the place in the genome 
according to the published genome sequence of the wild 
type strain. Bold white arrows indicate genes and their 
reading direction. Loci of non-coding RNAs are 
indicated by white boxes with angled arrows. Black 
boxes indicate non-neisserial DNA, in particular, 
kanamycin-resistance cassettes (Tn903). Vertical lines 
indicate CRISPR spacers. Restriction sites of ClaI and 
HindIII are given below the genes. The braces mark 
genome fragments after HindIII/ClaI, double digest 
hybridising with the Tn903-probe in Southern blot, and 
their computationally estimated size in bp. Drawn to 
scale. 
The WUE2594 cas9, rnc, and tracrRNA knockout strains 
demonstrated fragment sizes as expected (Figure 6.3) in 
the Southern blot. Strain WUE2594ΔCRISPR had one 
fragment of the expected size (5.4 kbp) but also a 
fragment of approximately 3.8 kbp, which is not 
computationally predicted. Even if a point mutation would 
alter the ClaI restriction site upstream the kanamycin 
restriction site and therefore inhibit the digestion, the 
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next ClaI restriction site would lead to a fragment 
significantly smaller than 3.8 kbp (see Figure 6.3).  
 
Figure 6.4 Southern blot analysis of 8013 cas9 mutant 
strains 
Southern blot analysis to verify the genotypes of 
8013Δcas9::Kmr and 8013Δcas9::Kmr Ccas9 strains. 
The genomic DNA of the mutant and the wild type 
strains were digested and used for Southern blot 
hybridisation with cas9 as probe.  
The Southern blot analysis of 8013 cas9 mutant strains 
showed cas9 detectable in the wild type and the 
complemented strains but not in the knockout-strains. 
Additionally, the cas9 knockout strains and the 
respective complemented strains in the genetic 
background of 8013 were verified via RT-PCR 
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(Figure 6.5), which demonstrates that cas9 is not 
transcribed in the knockout strains but in the 
complemented strains and the wild type. 
 
Figure 6.5 Gel electrophoresis of RT-PCR products from 
8013 cas9 mutant strains 
RT-PCR on cas9 with primer pair 1227 x 1228. 
Estimated size of the PCR product: 268 bp.  Bacteria 
were grown in GCBL++. RNA samples were isolated in 
late logarithmic growth phase and transcribed. An 
unpredicted product of approximately 400 bp is 
traceable in almost every positive PCR, which may be 
due to unspecific primer binding. Genomic DNA of 8013 
WT was used as a positive control (PC). DNA 
HyperLadder™ 1kb was used as a marker (M). 
Abbreviations: NC, negative control.  
NC 
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Since the WUE2594 CRISPR knockout strain did not 
show the expected fragment size, further PCR analyses 
were required. The binding sites of the primers used in 
PCRs for mutant verification are shown in Figure 5.2 and 
Figure 5.3. 
The PCRs performed to verify knockout strains are given 
in Table 6.1. The PCR conditions in particular are given 
in Table 5.5. Figure 6.6 shows the stained PCR products 
after gel electrophoresis. 
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Figure 6.6 PCR verification of mutant strains 
Products of PCRs performed to verify mutants in 8013 
(A) and WUE2594 (B). Each lane is labelled with a 
unique PCR identifier shown in Table 6.1. PCRs were 
performed as described in Table 5.5 using bacterial 
lysates as template. Depicted are the stained PCR 
products after gel electrophoresis. PCR products of 
unexpected size are marked by asterisks (*), PCRs that 
repeatedly failed are marked by crosses (+). The stained 
DNA HyperLadder™ 1kb is depicted next to the 
products and partially lettered in bp.  
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Table 6.1 Explanation of the PCR identifier  
PCR 
identifier 
strain primer 
expected 
 product size 
(bp) 
A-1-1 
8
0
1
3
 
Δ
C
R
IS
P
R
 
[A
H
-1
] 
1031 x 1032 2574 
A-1-2 1031 x 328 1069 
A-1-3 1032 x 329 1088 
A-5-1 
8
0
1
3
 
Δ
C
R
IS
P
R
 
[A
H
-5
] 
1031 x 1032 2574 
A-5-2 1031 x 328 1069 
A-5-3 1032 x 329 1088 
A-9-1 
8
0
1
3
 
Δ
tr
a
c
rR
N
A
 
 [
A
H
-9
] 
903 x 739 2517 
A-9-2 903 x 328 958 
A-9-3 739 x 329 1082 
A-15-1 
8
0
1
3
 Δ
rn
c
 C
rn
c
 
[A
H
-1
5
] 
988 x 989 2541 
A-15-2 988 x 971 1966 
A-15-3 989 x 970 1117 
A-15-4 970 x 971 665 
A-15-5 617 x 618 2653 
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PCR 
identifier 
strain primer 
expected 
 product size 
(bp) 
A-18-1 
8
0
1
3
 Δ
tr
a
c
rR
N
A
 
C
tr
a
c
rR
N
A
 
[A
H
-1
8
] 
988 x 989 1868 
A-18-2 988 x 1047 1466 
A-18-3 989 x 1048 618 
A-18-4 903 x 739 2517 
A-30-1 
8
0
1
3
 Δ
rn
c
 
[A
H
-3
0
] 
617 x 618 2653 
A-30-2 617 x 329 1220 
A-30-3 618 x 328 1016 
A-34-1 
8
0
1
3
 Δ
tr
a
c
rR
N
A
 C
c
a
s
9
 
[A
H
-3
4
] 
903 x 739 2517 
A-34-2 903 x 328 958 
A-34-3 739 x 329 1082 
A-34-4 1122 x 1123 4056 
A-34-5 976 x 1122 2514 
A-34-6 977 x 1123 2234 
A-38-1 
8
0
1
3
 Δ
rn
c
 C
rn
c
 
[A
H
-3
8
] 
988 x 989 2541 
A-38-2 988 x 970 1966 
A-38-3 989 x 971 1117 
A-38-4 970 x 971 665 
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PCR 
identifier 
strain primer 
expected 
 product size 
(bp) 
A-38-5 617 x 618 2653 
A-41-1 
8
0
1
3
 Δ
tr
a
c
rR
N
A
 
C
tr
a
c
rR
N
A
 
[A
H
-4
1
] 
988 x 989 1868 
A-41-2 988 x 1047 1466 
A-41-3 989 x 1048 618 
A-41-4 903 x 739 2517 
A-47-1 
8
0
1
3
 
Δ
tr
a
c
rR
N
A
 
 [
A
H
-4
7
] 903 x 739 2517 
A-47-2 903 x 328 958 
A-47-3 739 x 329 1082 
A-56-1 
8
0
1
3
 Δ
rn
c
 
[A
H
-5
6
/ 
 
B
J
-4
9
] 
617 x 618 2653 
A-56-2 617 x 329 1220 
A-56-3 618 x 328 1016 
A-65-1 
8013 
ΔtracrRNA 
 [AH-65] 
903 x 739 2517 
A-WT-1 8013 WT 1031 x 1032 3059 
A-WT-2 8013 WT 1031 x 328 - 
A-WT-3 8013 WT 1032 x 329 - 
A-WT-4 8013 WT 617 x 618 2172 
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PCR 
identifier 
strain primer 
expected 
 product size 
(bp) 
A-WT-5 8013 WT 988 x 971 - 
A-WT-6 8013 WT 989 x970 - 
A-WT-7 8013 WT 970 x 971 665 
A-WT-8 8013 WT 903 x 739 1423 
A-WT-9 8013 WT 1047 x 1048 202 
A-WT-10 8013 WT 988 x 1047 - 
A-WT-11 8013 WT 989 x 1048 - 
A-WT-12 8013 WT 977 x 1123 - 
A-WT-13 8013 WT 988 x 989 866 
A-WT-14 8013 WT 977 x 1123 - 
A-WT-15 8013 WT 1122 x 1123 - 
A-WT-16 8013 WT 617 x 329  
B-9-1 
W
U
E
2
5
9
4
 Δ
c
a
s
9
 
[B
J
-9
] 
905 x 906 2736 
B-9-2 905 x 329 1200 
B-9-3 906 x 328 1064 
B-9-4 976 x 977 - 
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PCR 
identifier 
strain primer 
expected 
 product size 
(bp) 
B-11-1 
W
U
E
2
5
9
4
 
Δ
tr
a
c
rR
N
A
 
[B
J
-1
1
] 
739 x 740 2651 
B-11-2 740 x 328 1105 
B-11-3 739 x 329 1082 
B-57-1 
W
U
E
2
5
9
4
 Δ
rn
c
 
[B
J
-5
7
] 
617 x 618 2699 
B-57-2 618 x 328 1015 
B-57-3 617 x 329 1220 
B-57-4 970 x 971 - 
B-70-1 
W
U
E
2
5
9
4
 
Δ
C
R
IS
P
R
 
[B
J
-7
0
] 
11604 x 11605 3160 
B-70-2 11605 x 328 1734 
B-70-3 11604 x 329 962 
B-70-4 972 x 973 - 
B-WT-1 
WUE2594 
WT 
905 x 906 4729 
B-WT-2 
WUE2594 
WT 
739 x 740 1570 
B-WT-3 
WUE2594 
WT 
617 x 618 2171 
B-WT-4 
WUE2594 
WT 
11604 x 11605 3399 
Results 
 
 
132 
PCR 
identifier 
strain primer 
expected 
 product size 
(bp) 
B-WT-5 
WUE2594 
WT 
976 x 977 546 
B-WT-5 
WUE2594 
WT 
970 x 971 665 
B-WT-6 
WUE2594 
WT 
972 x 973 661 
 
The 8013 and the WUE2594 mutant strains were 
successfully verified by PCR analysis and showed the 
computationally predicted product sizes. Only the PCRs 
using the primer combination 903x328 failed repeatedly, 
possibly due to bad primer compatibility. The PCR 
A-34-4 amplifies a product larger than 4000 bp and was 
not performable using Taq polymerase. 
Overall, the generated mutant strains were in line with 
the expectations. 
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6.2 Influence of the genetic alterations on 
the phenotype of 8013 and WUE2594 
mutant strains 
6.2.1 Macroscopic aspect of WUE2594 and 
8013 mutant strains on COS agar plates 
On many occasions during the experiments, the strains 
were cultivated on COS agar plates. It was continuously 
observable that the colonies of the N. meningitidis 
WUE2594 rnc knockout strain were smaller than other 
WUE2594 strains plated at the same time (Figure 6.7). 
This effect was not observable in N. meningitidis 8013. 
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Figure 6.7 Macroscopic aspect of the WUE2594 and 
8013 mutant strains as colonies on COS plates 
Liquid cultures of the strains were adjusted to 
OD600 = 1.0, plated on COS plates, and incubated 
overnight at 37 °C and 5% CO2. The photographs were 
taken using the ProtoCOL colony counter (Table 4.1). 
Depicted are equally scaled, representative parts of an 
entire agar plate.  
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6.2.2 Bacterial growth of WUE2594 mutant 
strains in liquid culture 
The macroscopic aspect of the WUE2594 rnc knockout 
strain might indicate a growth deficiency of this strain. To 
exclude the presence of global phenotypic effects 
influencing further experiments, the in vitro growth of the 
strains in RPMI+ (Table 4.25) was examined. The results 
are depicted in Figure 6.8. Since the adhesion and 
invasion assays with WUE2594 strains were only 
performed in RPMI+, the growth of WUE2594 strains in 
EMEM+++ was not assessed.  
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Figure 6.8 Growth of WUE2594 strains in RPMI+ 
WUE2594 wild type and mutant strains were grown in 
RPMI+ for 10 h at 37 °C, and the optical density (OD600) 
was determined every hour (A). After 0 h, 5 h, and 9 h 
of incubation, the suspensions were serially diluted, and 
three dilution steps were plated twice on COS agar 
plates. After overnight incubation, the CFU was 
measured using the ProtoCol colony counter . Depicted 
are the weighted mean values and the standard 
deviations of six measurements (B). 
A 
B 
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Even though hourly measuring of the OD600 did not 
reveal differences in growth between WUE2594 mutant 
strains, the counted CFU of the rnc knockout were 
reduced compared to the wild type strain after 9 h of 
growth.  
6.2.3 Bacterial growth of 8013 mutant strains 
in liquid culture 
6.2.3.1 8013 mutant strains are able to 
survive in EMEM+++ 
To preserve vital host cells, the cell adhesion and 
invasion assays had to be performed using EMEM+++ as 
culture medium. While EMEM+++ is a nutrient-rich 
medium (Table 4.23), the capability of N. meningitidis 
8013 and the mutant strains to survive and grow in 
EMEM+++ had to be assessed.   
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Figure 6.9 Growth of 8013 strains in EMEM+++ 
8013 wild type (WT) with corresponding mutant strains 
and respective complementant strains were grown in 
EMEM+++ for 8 h at 37 °C, and the optical density 
(OD600) was determined every hour. Depicted are the 
mean values of three individual measurements.  
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While every mutant strain was able to survive in 
EMEM+++, two out of three cas9 knockouts, AH-23 and 
AH-25 (Figure 6.9 B and C), and both rnc knockouts, 
AH-30 and BJ-49 (Figure 6.9 F and G), demonstrated 
decreased growth capacity. The growth defect was 
diminished by rnc complementation (Figure 6.9 F) but 
only partially by cas9 complementation (Figure 6.9 B and 
C) in the respective mutant strain. 
Since it has been shown that RNase III is a global 
regulator of gene expression in E. coli [94], it is 
conceivable that the knockout of rnc in a N. meningitidis 
strain leads to a growth deficiency, and this assumption 
is strengthened since the effect was absent in the 
complemented strain AH-15. An influence of Cas9 on the 
bacterial growth has not been described yet. 
Furthermore, since the effect was absent in strain AH-12 
(Figure 6.9 A) and only partially restored in the 
complemented strains AH-22 and AH-24 (Figure 6.9 B 
and C), it is possible that a second genetic event 
occurred during the knockout of cas9 in AH-23 and 
AH-25 that influences the growth capacity in EMEM+++. 
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6.2.3.2 The knockout of cas9 does not lead 
to a general growth deficiency  
To examine whether the growth capacity of the cas9 
knockout strains is medium dependent, the growth 
experiments were also performed in GCBL++ 
(Table 4.16). GCBL++ is also a nutrient-rich medium and 
known to be suitable for meningococcal growth [95]. 
Under these conditions, all mutant strains demonstrated 
growth similar to the wild type (Figure 6.10). 
 
Figure 6.10 Growth of 8013 cas9 mutant strains in 
GCBL++ 
8013 wild type, mutant, and respective complementant 
strains were grown in GCBL++ for 7 h at 37 °C, and the 
optical density (OD600) was determined every hour. 
Depicted are the mean values of two individual 
measurements. 
Results 
 
 
144 
6.2.4 N. meningitidis 8013 does not form static 
biofilm in EMEM+++ 
It has been shown that N. meningitidis forms biofilms on 
abiotic and biotic surfaces [96, 97], and biofilm formation 
might influence the adhesion of meningococci to host 
cells [15]. To examine whether the knockout of 
CRISPR/Cas related genes influences biofilm formation 
under static conditions, biofilm formation was assessed 
in a polystyrene microtiter plate as described in 
Chapter 5.26.  
To ensure conditions comparable to the cell adhesion 
and invasion assay (Chapter 5.25), the static biofilm 
assay was performed in EMEM+++ cell culture medium 
(Table 4.22). Neither the wild type nor one of the tested 
knockouts formed a significant biofilm layer in EMEM+++ 
(Figure 6.11). 
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Figure 6.11 Biofilm formation of 8013 mutant strains 
8013 wild type, mutant, and respective complementant 
strains were cultured in EMEM+++, and the static biofilm 
formation was determined after 16 h of incubation.  The 
assay was performed on a 96-well microtiter plate as 
described in Chapter 5.26. To quantify the biofilm 
formation, the biofilms were stained using crystal violet 
and the OD595 was measured. The threshold of 
significant biofilm formation was determined by staining 
and measuring uninoculated wells and multiplying the 
measured value by three. Depicted is one out of three 
similar experiments representing mean values of six 
technical replicates.  
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6.3 The CRISPR/Cas system influences the 
adhesion to host cells in a strain specific 
manner  
The ability of meningococci to adhere to human host 
cells and to invade the cells is a crucial step in the 
development of IMD [6, 7]. 
To examine the influence of the CRISPR/Cas system on 
the interaction with human host cells, cell adhesion and 
invasion assays (Chapter 5.25) were performed on a 
nasopharyngeal cell line called Detroit562. Detroit562 
cells are derived from pleural effusion caused by the 
metastasis of a nasopharyngeal carcinoma in a female 
Caucasian [85, 86]. They were cultivated in EMEM+++ 
and infected with the meningococcal strains. After 4 
hours of infection, the number of adherent bacteria were 
determined as described in Chapter 5.25. Subsequently, 
the cells were treated with gentamicin, a bactericidal 
aminoglycoside antibiotic that irreversibly binds to the 
30S subunit of the bacterial ribosome and inhibits protein 
synthesis [98]. Gentamicin cannot invade Detroit562 
cells and is therefore unable to kill intracellularly and 
thus invasive meningococci. After 1 h of gentamicin 
treatment, the Detroit562 cells were lysed using saponin 
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and the gentamicin-protected invasive bacteria were 
determined as described in Chapter 5.25. 
6.3.1 The adhesion and invasion to host cells 
is CRISPR/Cas independent in WUE2594 
Ten individual adhesion and invasion assays were 
performed with WUE2594 strains and examined the wild 
type and two knockout strains simultaneously. The order 
of the strains in the experimental setup was appointed 
randomly to prevent bias. As shown in Table 6.2, the 
knockouts did not differ in their mean adhesion or in their 
mean invasion rate compared to the wild type.  
Four out of six experiments performed with the 
WUE2594 cas9 knockout strain (BJ-3) showed an 
adhesion and invasion rate similar to the wild type. In 
one experiment, the adhesion and invasion rate were 
reduced (α < 0.05) and in one experiment the adhesion 
and invasion rate were significantly (α < 0.01) increased.  
The WUE2594 tracrRNA knockout BJ-11 was tested four 
times: three times with results similar to the wild type and 
one time with an increased adhesion rate (α < 0.05). 
The adhesion rate of the WUE2594 rnc knockout strain 
(BJ-57) was reduced in two out of six experiments, both 
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times with a moderate significance (α < 0.05). In one 
experiment the invasion rate was reduced while in the 
other it was increased (both α < 0.05). The other four 
experiments showed results similar to the wild type. 
The knockout of the CRISPR array in WUE2594 (BJ-70) 
led to inconsistent results in the adhesion and invasion 
assay. The adhesion rate was significantly (α < 0.01) 
decreased twice, and the invasion rate increased. One 
experiment showed an opposite result, an increased 
adhesion rate, and a decreased invasion rate, and one 
experiment produced results similar to the wild type. 
Therefore, no consistent effect of the CRISPR/Cas 
system on host cells interaction was observed in strain 
WUE2594.  
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Table 6.2 Adhesion and invasion rates of WUE2594 
knockout strains 
Listed are the observed adhesion rates relative to the 
wild type (rel. adh. rate, in bold) (A) and (B) and 
invasion rates relative to the wild type (rel. inv. rate, in 
bold) (C) and (D) on Detroit562 cells and the respective 
standard deviation (st. dev.) of the WUE2594 knockout 
strains as well as the p-value comparing the mutant 
adhesion or invasion rate relative to the wild type. The 
mean adhesion rate of the wild type over the depicted 
10 experiments was 0.747 (SEM 1.95*10-1), and the 
mean invasion rate was 7.55*10-4 (SEM 1.40*10-4). The 
ID-number of each experiment (n) is given in square 
brackets below the values. The experiments were 
performed with two knockout strains and the wild type 
strain simultaneously. The mean relative adhesion rates 
(B) and invasion rates (D) of the knockout strains and 
the respective standard error of the mean are given 
below each column of individual results. Abbreviations: 
n.d., no data; n.s., not significant (α  > 0.05) 
6.3.2 The knockout of cas9, tracrRNA and rnc 
leads to a reduced adhesion rate in 8013 
In contrast to WUE2594, 8013 showed almost no 
invasive behaviour in Detroit562 cells. The COS plates 
with the gentamicin protected bacteria were grown with 
less than thirty colonies in the lowest dilution stage. 
Therefore, only the adhesion rate of 8013 was examined 
(Table 6.3).  
Results 
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Three biological replicates of the 8013 cas9 knockout 
were tested, AH-12, AH-25 and BJ-3 (named AH-23 
after transformation of an empty plasmid). AH-12 was 
tested two times, BJ-3, three times. All five experiments 
showed a significantly (α < 0.01) reduced adhesion rate 
of the cas9 knockout strain. Strain AH-23 and AH-25 
were examined together with the corresponding 
complementant strain (see Chapter 6.3.3). 
The 8013 tracrRNA knockout strain (AH-9) was used in 
three experiments and its adhesion rate was significantly 
(α < 0.01) reduced every time compared to the wild type.  
The knockout of rnc in 8013 leads to a reduced adhesion 
rate (α < 0.01) in the five experiments, performed with 
two biological replicates, BJ-49 and AH-30.  
However, the adhesion rate of the 8013 CRISPR 
knockouts adhesion rate was increased in four out of five 
experiments performed with two biological replicates 
(AH-1 and AH-5). In one experiment, the 8013 CRISPR 
knockout strain AH-5 showed an increased adhesion 
rate but with a high standard deviation and thus without 
statistical significance.  
Results 
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Overall, the mean adhesion rates of the cas9, the 
tracrRNA and the rnc knockout in 8013 were decreased 
and notably they were reduced to a similar level. The 
mean adhesion rates of the CRISPR knockout strains 
were increased with large fluctuations between the 
individual experiments and biological replicates.  
Results 
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Table 6.3 Adhesion rates of 8013 knockout strains 
Listed are the observed adhesion rates relative to the 
wild type (rel. adh. rate, in bold) on Detroit562 cells and 
the respective standard deviation (st. dev.) of the 8013 
knockout strains as well as the p-value comparing the 
adhesion rate of the mutant strain to the wild type. The 
mean adhesion rate of the wild type over the depicted 
10 experiments was 1.05 (SEM 3.3*10-1). The ID-
number of each experiment (n) is given in square 
brackets below the values. The experiments were 
performed with two knockout strains and the wild type 
strain simultaneously. The mean relative adhesion rates 
of the knockout strains and the respective standard 
error of the mean are given next to each row of 
individual results. Abbreviations: n.d., no data; n.s., not 
significant (α > 0.05) 
6.3.3 The effect of the cas9 and rnc knockout 
on the adhesion to host cells is 
complementable 
To determine whether the observed effect of the cas9, 
the tracrRNA and the rnc knockout on the adhesion to 
human host cells (Chapter 6.3.2) is complementable, the 
8013 mutant strains were examined with the 
corresponding complementant strains simultaneously 
(Table 6.4).  
Results 
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Table 6.4 Adhesion rates of 8013 knockout strains and 
complementant strains 
Listed are the adhesion rates on Detroit562 cells and 
the respective standard deviation (st. dev.) of the 8013 
knockout strains along with their respective 
complementant strain as well as the p-values comparing 
the mutant’s adhesion rate to the wild type and the 
complementant strain. The mean adhesion rate of the 
wild type over the depicted 17 experiments was 0.947 
(SEM 1.40*10-1). The experiments were performed with 
knockout, complementant, and wild type strain 
simultaneously. The mean relative adhesion rates of the 
knockout strains and the respective standard error of 
the mean are given next to each row of individual 
results. Abbreviations: n.d., no data; n.s., not significant 
(α > 0.05) 
The reduced adhesion rate of AH-12 was consistently 
observable in each experiment, whereas the 
complemented strain AH-61 showed adhesion rates 
similar to the wild type. The cas9 knockout strains AH-23 
and AH-25 were tested together with their 
complementant strains AH-24 and AH-22 with 
comparable results. 
The adhesion rate of the 8013 tracrRNA knockout strain 
BJ-45 was significantly reduced in the experiments, but 
the effect was only partially complementable, since the 
complementant strain AH-18 showed adhesion rates 
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significantly higher than BJ-45 but significantly lower 
than the wild type strain. Because of its proximity in the 
genome, a polar effect of the tracrRNA knockout on cas9 
was conceivable. However, the complementation of cas9 
into the 8013 tracrRNA knockout strain BJ-45 had no 
effect on the adhesion rate. In four out of four 
experiments, the cas9 complemented tracrRNA 
knockout strain AH-34 showed a decreased adhesion 
rate compared to the wild type. In three out of four 
experiments, the adhesion rate was similar to the 
knockout, and only once was the adhesion rate of AH-34 
significantly higher than its knockout. Thus, the knockout 
of tracrRNA is not complementable with a second copy 
of cas9. 
In every experiment performed with the 8013 rnc 
knockout strain BJ-49, the adhesion rate was decreased 
compared to the wild type and the adhesion rate of the 
complemented strain AH-15 was significantly higher. The 
complemented strain showed adhesion rates on wild 
type level in two out of three experiments. The rnc 
knockout strain AH-30 was tested together with the 
complementant strains AH-38 and AH-22, with similar 
results. 
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The 8013 CRISPR knockout were not complementable 
in the way the other knockouts were (Chapter 5.18), 
which may be due to the frequent repeats. Therefore, the 
8013 CRISPR knockouts were not tested further 
(Table 6.3). 
Overall, effects of the knockouts on the adhesion rate 
demonstrated in Chapter 6.3.2 were confirmed and 
shown to be complementable for cas9 and rnc and 
partially complementable for tracrRNA (Figure 6.12, 
Table 6.4). Notably, the integration of an empty plasmid 
in BJ-3 and BJ-45 did not alter the effect of the knockout 
on the adhesion rate. 
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Figure 6.12 Adhesion of 8013 CRISPR/Cas mutant 
strains to the human nasopharyngeal epithelial cell 
line Detroit562 
Depicted is the average adhesion rate of each mutant 
strain relative to the wild-type strain (set to 100%) from 
three independent experiments as shown in Table 6.4. 
The error bars indicate the standard error of the mean. 
For each strain, the adhesion rate was calculated as the 
number of colony-forming units (CFU) determined after 
4 h of infection divided by the seeded CFU. The relative 
adhesion rate is the adhesion rate of the mutant divided 
by the adhesion rate of the wild-type strain.  
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6.4 The CRISPR/Cas loci of Neisseria strains 
differ in sequence 
Since the knockout of genes of the CRISPR/Cas system 
in the two different strains WUE2594 and 8013 lead to 
different results in the performed experiments, 
computational analysis of the genes of interest were 
conducted to assess the genetic similarity of the strains. 
Therefore, the nucleotide sequences of the respective 
genes in 8013 were compared to the Neisseria genomes 
published on NCBI using the NCBI blastn search 
(Chapter 5.27) and the megablast algorithm. As a result 
of the query, bitscores were obtained for each alignment. 
A higher bitscore corresponds to a higher similarity. To 
simplify the comparison between the examined strains, 
the bitscores were divided by the bitscore obtained for 
the 8013 self-hit to obtain a bit score normalized ratio 
(BSNR). Thus, the correct identity is given with 
BSNR = 1.0, whereas any result <1.0 refers to a lower 
grade of similarity. As an indicator for the overall 
similarity of the genome to 8013, highly conserved 
housekeeping genes were included in the query. In 
particular, adk which encodes for the adenylate kinase, 
pip encoding the proline iminopeptidase and serC, which 
Results 
 
 
162 
encodes for the phosphoserine aminotransferase, were 
used [99]. 
The nucleotide sequences of cas1, cas2, cas9, the 
CRISPR array, the tracrRNA, rnc, adk, pip, and serC 
from N. meningitidis 8013 were compared to 25 
Neisseria genomes. Fourteen lacked a CRISPR/Cas 
system (data not shown). The other eleven were 
compared as described above and the results are listed 
in Table 6.5. To estimate the overall variance of a gene, 
the coefficient of variation (Cv) is given above the table.  
The comparison revealed that none of the published 
strains has a Cas9 gene identical in sequence to 8013. 
However, the cas9 sequence of the strains 
N. meningitidis WUE2594, N. meningitidis Z2491, 
N. meningitidis α14, N. meningitidis M01-240355, and 
N. meningitidis 51062 are very similar to N. meningitidis 
8013. It is noteworthy that these strains belong to 
different serogroups. The strains N. meningitidis 
DE10444 and N. meningitidis α153 harbour a cas9 
sequence that is strikingly different to the cas9 sequence 
of 8013. 
The sequence of the tracrRNA was identical in every 
strain, whereas the CRISPR array had a great variance 
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(Cv = 0.96). Overall, the sequences of cas1 and cas2 are 
as highly conserved as those of adk and pip, and the 
sequence of cas9 has a coefficient of variation as low as 
serC.  
Table 6.5 Similarity of genes in sequenced Neisseria 
genomes compared to N. meningitidis 8013 
  BSNR
b   
𝑏𝑖𝑡𝑠𝑐𝑜𝑟𝑒 (𝑔𝑒𝑛𝑒 8013 → 𝑔𝑒𝑛𝑜𝑚𝑒 𝑟𝑒𝑞𝑢𝑒𝑠𝑡𝑒𝑑 𝑠𝑡𝑟𝑎𝑖𝑛)
𝑏𝑖𝑡𝑠𝑐𝑜𝑟𝑒 (𝑔𝑒𝑛𝑒 8013 → 𝑔𝑒𝑛𝑜𝑚𝑒 8013)
  
Genome sg.a 
c
a
s
1
 
c
a
s
2
 
c
a
s
9
 
C
R
IS
P
R
 
tr
a
c
rR
N
A
 
rn
c
 
a
d
k
 
p
ip
 
s
e
rC
 
Acc-Noc 
 
 
N. meningitidis 
CV 0.05 0.02 0.11 0.96 0.00 0.05 0.03 0.06 0.11  
8013 B 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 FM999788.1 
WUE2594 A 0.92 1.00 0.98 0.25 1.00 0.95 0.93 0.96 0.95 FR774048.1 
Z2491 A 0.92 1.00 0.98 0.19 1.00 0.95 0.96 0.97 0.97 AL157959.1 
053443 C 0.85 0.98 0.92 0.12 1.00 0.85 0.95 0.97 0.96 CP000381.1 
α14 cnl 0.95 1.00 0.98 0.08 1.00 0.93 0.94 1.00 0.96 AM889136.1 
M01-240355 B 0.89 0.97 0.98 0.26 1.00 0.88 0.97 0.95 0.97 CP002422.1 
510612 A 0.92 1.00 0.98 0.27 1.00 0.95 0.93 0.96 0.95 CP007524.1 
Results 
 
 
164 
DE10444 n.d. 0.94 0.95 0.72 0.19 1.00 0.92 1.00 0.95 0.95 unpublished 
α153 n.d. 0.84 0.98 0.79 0.15 1.00 0.93 0.98 0.95 0.93 unpublished 
α275 n.d. 0.92 1.00 0.96 0.26 1.00 0.91 0.97 0.95 0.94 unpublished 
 
a serogroup of the strain; abbreviations: cnl, capsule null locus; n.d., 
not determined; n.s., not suitable  
b Bit Score Normalized Ratio  
c Accession-Number  
d coefficient of variation 
6.5 Both strains express a highly similar 
Cas9 protein 
Further comparison of the amino acid sequence of Cas9 
in strain 8013 and strain WUE2594 revealed that the 
difference in nucleotide sequence leads to nine amino 
acid mismatches (Figure 6.13). Only one of those 
mismatches is located inside a functional domain, 
concerning the Arginine-rich motive (ARM). Those 
motives are known to mediate the protein-RNA 
interaction [100]. The C-terminal end of Cas9 is known to 
determine the recognized protospacer-adjacent motive 
(PAM) [101]. Since the mismatches between 8013 and 
WUE2594 accumulate in the N-terminal region of Cas9, 
the two orthologs will likely target identical PAM.  
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                      10 RuvC-I  20         30         40         50              
8013         MAAFKPNSIN YILGLDIGIA SVGWAMVEID EEENPIRLID LGVRVFERAE  
WUE2594      MAAFKPNPIN YILGLDIGIA SVGWAMVEID EDENPICLID LGVRVFERAE  
 
                      60 ARM     70         80         90        100             
8013         VPKTGDSLAM ARRLARSVRR LTRRRAHRLL RTRRLLKREG VLQAANFDEN  
WUE2594      VPKTGDSLAM ARRLARSVRR LTRRRAHRLL RARRLLKREG VLQAADFDEN  
 
                      110        120 RuvC-II130        140        150         
8013         GLIKSLPNTP WQLRAAALDR KLTPLEWSAV LLHLIKHRGY LSQRKNEGET  
WUE2594      GLIKSLPNTP WQLRAAALDR KLTPLEWSAV LLHLIKHRGY LSQRKNEGET  
 
                      160        170        180        190        200         
8013         ADKELGALLK GVAGNAHALQ TGDFRTPAEL ALNKFEKESG HIRNQRSDYS  
WUE2594      ADKELGALLK GVADNAHALQ TGDFRTPAEL ALNKFEKESG HIRNQRGDYS  
 
                      210        220        230        240        250         
8013         HTFSRKDLQA ELILLFEKQK EFGNPHVSGG LKEGIETLLM TQRPALSGDA  
WUE2594      HTFSRKDLQA ELILLFEKQK EFGNPHVSGG LKEGIETLLM TQRPALSSDA  
 
                      260        270        280        290        300         
8013         VQKMLGHCTF EPAEPKAAKN TYTAERFIWL TKLNNLRILE QGSERPLTDT  
WUE2594      VQKMLGHCTF EPAEPKAAKN TYTAERFIWL TKLNNLRILE QGSERPLTDT  
 
                      310        320        330        340        350         
8013         ERATLMDEPY RKSKLTYAQA RKLLGLEDTA FFKGLRYGKD NAEASTLMEM  
WUE2594      ERATLMDEPY RKSKLTYAQA RKLLGLEDTA FFKGLRYGKD NAEASTLMEM  
 
                      360        370        380        390        400         
8013         KAYHAISRAL EKEGLKDKKS PLNLSPELQD EIGTAFSLFK TDEDITGRLK  
WUE2594      KAYHAISRAL EKEGLKDKKS PLNLSPELQD EIGTAFSLFK TDEDITGRLK  
 
                      410        420        430        440        450         
8013         DRIQPEILEA LLKHISFDKF VQISLKALRR IVPLMEQGKR YDEACAEIYG  
WUE2594      DRIQPEILEA LLKHISFDKF VQISLKALRR IVPLMEQGKR YDEACAEIYG  
 
                      460        470        480        490        500         
8013         DHYGKKNTEE KIYLPPIPAD EIRNPVVLRA LSQARKVING VVRRYGSPAR  
WUE2594      DHYGKKNTEE KIYLPPIPAD EIRNPVVLRA LSQARKVING VVRRYGSPAR  
 
             RuvC-III 510        520        530        540        550         
8013         IHIETAREVG KSFKDRKEIE KRQEENRKDR EKAAAKFREY FPNFVGEPKS  
WUE2594      IHIETAREVG KSFKDRKEIE KRQEENRKDR EKAAAKFREY FPNFVGEPKS  
 
                      560        570        580   HNH  590        600         
8013         KDILKLRLYE QQHGKCLYSG KEINLGRLNE KGYVEIDHAL PFSRTWDDSF  
WUE2594      KDILKLRLYE QQHGKCLYSG KEINLGRLNE KGYVEIDHAL PFSRTWDDSF  
 
                      610        620        630        640        650         
8013         NNKVLVLGSE NQNKGNQTPY EYFNGKDNSR EWQEFKARVE TSRFPRSKKQ  
WUE2594      NNKVLVLGSE NQNKGNQTPY EYFNGKDNSR EWQEFKARVE TSRFPRSKKQ  
 
                      660        670        680        690        700         
8013         RILLQKFDED GFKERNLNDT RYVNRFLCQF VADRMRLTGK GKKRVFASNG  
WUE2594      RILLQKFDED GFKERNLNDT RYVNRFLCQF VADRMRLTGK GKKRVFASNG  
 
                      710RuvC-IV 720        730        740        750         
8013         QITNLLRGFW GLRKVRAEND RHHALDAVVV ACSTVAMQQK ITRFVRYKEM  
WUE2594      QITNLLRGFW GLRKVRAEND RHHALDAVVV ACSTVAMQQK ITRFVRYKEM  
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Figure 6.13 Sequence alignment of Cas9 
Amino acid sequence alignment of strain 8013 and 
strain WUE2594 Cas9 generated by CUSTALW [88]. 
Amino acids are annotated in one-letter code [102] and 
sorted in packages of ten amino acids. Mismatches are 
highlighted as white text on black background. Grey 
shaded boxes represent the functional domains of Cas9.  
Four RuvC endonuclease domains (RuvC-I through 
RuvC-IV), an HNH endonuclease domain, and an 
Arginine-Rich Motive (ARM) have been predicted for 
Cas9 [35]. The HNH nuclease domain cleaves the DNA 
strand complementary to the CRISPR RNA and the 
RuvC-like domain cleaves the non-complementary 
strand [38]. 
  
                      760        770        780        790        800         
8013         NAFDGKTIDK ETGEVLHQKT HFPQPWEFFA QEVMIRVFGK PDGKPEFEEA  
WUE2594      NAFDGKTIDK ETGEVLHQKT HFPQPWEFFA QEVMIRVFGK PDGKPEFEEA  
 
                      810        820        830        840        850         
8013         DTLEKLRTLL AEKLSSRPEA VHEYVTPLFV SRAPNRKMSG QGHMETVKSA  
WUE2594      DTPEKLRTLL AEKLSSRPEA VHEYVTPLFV SRAPNRKMSG QGHMETVKSA  
 
                      860        870        880        890        900         
8013         KRLDEGVSVL RVPLTQLKLK DLEKMVNRER EPKLYEALKA RLEAHKDDPA  
WUE2594      KRLDEGVSVL RVPLTQLKLK DLEKMVNRER EPKLYEALKA RLEAHKDDPA  
 
                      910        920        930        940        950         
8013         KAFAEPFYKY DKAGNRTQQV KAVRVEQVQK TGVWVRNHNG IADNATMVRV  
WUE2594      KAFAEPFYKY DKAGNRTQQV KAVRVEQVQK TGVWVRNHNG IADNATMVRV  
 
                      960        970        980        990        1000        
8013         DVFEKGDKYY LVPIYSWQVA KGILPDRAVV QGKDEEDWQL IDDSFNFKFS  
WUE2594      DVFEKGDKYY LVPIYSWQVA KGILPDRAVV QGKDEEDWQL IDDSFNFKFS  
 
                      1010       1020       1030       1040       1050        
8013         LHPNDLVEVI TKKARMFGYF ASCHRGTGNI NIRIHDLDHK IGKNGILEGI  
WUE2594      LHPNDLVEVI TKKARMFGYF ASCHRGTGNI NIRIHDLDHK IGKNGILEGI  
 
                      1060       1070       1080      
8013         GVKTALSFQK YQIDELGKEI RPCRLKKRPP VR 
WUE2594      GVKTALSFQK YQIDELGKEI RPCRLKKRPP VR 
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7 Discussion 
Studies have demonstrated that genes located at the 
CRISPR/Cas locus are more frequent in carriage strains 
of meningococci than in strains from hyperinvasive 
lineages [19]. Furthermore, Cas9 has been shown to 
repress the endogenous transcript of a bacterial 
lipoprotein (blp) in Francisella novicida, thus affecting 
virulence, and it has been assumed that Cas9 also fulfils 
similar functions in N. meningitidis [35]. Studies 
regarding the N. meningitidis serogroup W135 strain 
92045 investigated the interaction with A549 cells 
derived from a human lung adenocarcinoma. Since 
pneumonia is a rare end-organ manifestation of IMD, the 
medical relevance of these experiments seems 
questionable [43]. A crucial step in developing IMD is 
crossing the mucosal surface of the nasopharynx by 
penetrating the epithelial or endothelial cells [103]. 
Therefore, this study examined the influence of the 
CRISPR/Cas system on the adhesion to and invasion of 
a human nasopharyngeal cell line. 
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7.1 The impact of the CRISPR/Cas system 
on the adhesion to host cells depends 
on the genetic background 
The adhesion assays performed using 8013 mutant 
strains revealed a significant reduction of the adhesion 
rates for strains carrying individual deletions of cas9, 
tracrRNA, or rnc (Chapter 6.3.2). The adhesion rates of 
the cas9 knockout and the rnc knockout strain could be 
restored to the wild type level by complementing the 
respective genes in trans by integrating rnc into the porA 
and cas9 into the lctP and aspC locus (see Chapter 5.18 
and 6.3.3). Notably, this confirms the preceding 
experiments using N. meningitidis strain 92045, which 
demonstrate that Cas9 is required for meningococcal 
adhesion to human adenocarcinoma alveolar basal 
epithelial cells [35]. Neither the attempts to complement 
the ΔtracrRNA mutant by integrating a copy of tracrRNA 
in trans into the porA locus nor, assuming a polar effect 
of the tracrRNA knockout on cas9 expression, the 
integration of a second copy of cas9 in trans into the lctP 
and aspC locus restored the adhesion rate to wild type 
level (Table 6.4). The knockout of the CRISPR array did 
not lead to consistent effects, but it increased the 
adhesion rate rather than diminish it, perhaps due to a 
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hyperactivity of Cas9 in the absence of crRNAs. Neither 
the wild type 8013 strain nor any mutant showed 
invasive behaviour on the epithelial cells.  
In contrast to the results obtained for 8013, the deletion 
mutants in WUE2594 did not differ in their interaction 
with human host cells compared to the wild type, even 
though the CRISPR/Cas locus of 8013 and WUE2594 
are, despite the CRISPR spacers, highly similar. The 
CRISPR spacers are acquired sequences derived from 
previously encountered invasive DNA [25]. Therefore, it 
is unsurprising that the CRISPR spacer of 8013 and 
WUE2594 differ in sequence and number [45]. 
The tracrRNA is identical in both strains (Table 6.5) but 
cas9 and rnc are not. There are nine differences in the 
amino acid sequence of Cas9 in N. meningitidis 8013 
and WUE2594, but those are mostly outside of functional 
domains (Figure 6.13). Only one mismatch concerns a 
functional domain called ARM, which is known to 
mediate protein-RNA interaction [35]. While strain 8013 
has a polar threonine at position 82, WUE2594 has a 
nonpolar alanine instead (see Figure 6.13). Noteworthy, 
in F. novicida a single point mutation in the ARM 
completely abolished the ability of Cas9 to repress 
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blp [35]. Furthermore, it has been shown recently that 
the different Cas9 orthologs present in sequenced 
N. meningitidis strains recognize three different PAM 
depending on their C-terminal sequence [101]. The 
nucleotide sequence of the RNase III- encoding gene rnc 
is almost identical between 8013 and WUE2594 and 
thus is as highly conserved as housekeeping genes such 
as adk, pip, or serC (Table 6.5). Minor differences are 
unsurprising regarding the immense variations observed 
between strains, even of the same clonal complex [19]. 
Therefore, the alterations in the sequence of rnc are 
unlikely to be responsible for the observed differences in 
cas9 deletion strains. 
It is more likely that the distinct results are due to the 
different genetic background of these strains. The target 
of the gene-regulating function of Cas9 in N. meningitidis 
is still unknown. 
7.2 Limitations of the adhesion and invasion 
assay 
The observed effects of the genetic alterations on the 
results of the adhesion and invasion assay are not 
necessarily caused by a diminished capacity to adhere 
to host cells. A global growth defect would probably also 
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reduce the measured number of bacteria after 4 h of 
incubation. To address this method problem, the growth 
capacity of the mutants was examined. However, the 
results of the growth experiments did not correlate with 
the results of the adhesion and invasion assay 
(Table 7.1). On the contrary, there were strains, for 
example AH-24, with a reduced growth capacity in 
EMEM+++ and a wild-type-like adhesion rate. Apparently, 
those traits are not necessarily linked. Additionally, there 
are differences in the growth conditions even though 
both experiments used EMEM+++ as culture medium. The 
growth experiments were performed in liquid culture 
under rigorous shaking in contrast to the adhesion and 
invasion assays (see Chapter 5.23). Furthermore, 
bacterial cells had to share the medium with eukaryotic 
cells in the adhesion and invasion assay. Thus, the pH 
and nutrient content of the medium shifted during the 
experiment. However, comparison of the growth of 8013 
strains in EMEM+++ and GCBL++ demonstrates that the 
growth deficiency is medium specific (Chapter 6.2.3.2). 
Therefore, the results of the growth experiments are at 
best partially responsible for the observed differences in 
the adhesion and invasion assay.  
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Table 7.1 Observed phenotypes of the 8013 mutant 
strains compared to the wild type strain 
8013 mutant strain 
Growth in 
Adhesion 
ratec 
EMEM+++a GCBL++b 
∆cas9 (AH-12) = = ↓ 
∆cas9 Ccas9 (AH-61) = = = 
∆cas9 (AH-23) ↓ = ↓ 
∆cas9 Ccas9 (AH-24) ↓ = = 
∆cas9 (AH-25) ↓ = ↓ 
∆cas9 Ccas9 (AH-22) ↓ = = 
∆tracrRNA (B-45/ AH-65) = - ↓ 
∆tracrRNA CtracrRNA (AH-18) = - = / ↓ 
∆tracrRNA Ccas9 (AH-34) - - ↓ 
∆tracrRNA (AH-47) = - ↓ 
∆tracrRNA CtracrRNA (AH-41) = - - 
∆rnc (B-49) ↓ - ↓ 
∆rnc Crnc (AH-15) = - = 
∆rnc (AH-30) ↓ - ↓ 
∆rnc Crnc (AH-38) - - = 
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8013 mutant strain 
Growth in 
Adhesion 
ratec 
EMEM+++a GCBL++b 
∆CRISPR (AH-1) ↓ - = 
∆CRISPR (AH-5) - - = / ↑ 
 
↓ decreased compared to the wild type; ↑ increased compared to the 
wild type; = similar to wild type; - no data 
a see Figure 6.9 
b see Figure 6.10 
c see Table 6.3 and Table 6.4 
 
Another possible confounder is the capacity to build 
biofilms, since biofilm formation enhances antibiotic 
resistance and increases the stability against mechanical 
stress [104, 105]. However, no biofilm formation was 
observed on abiotic surfaces in EMEM+++ for strain 8013. 
Thus, the obtained results in the adhesion and invasion 
assay are unlikely to be affected by biofilm formation. 
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7.3 Potential mode of action of Cas9 on cell 
adhesion 
Since no experimental evidence indicates that Cas9 
interacts directly with human host cells, it has to be 
assumed that Cas9 somehow modulates the activity of 
at least one bacterial adhesin and/or the integrity of the 
bacterial cell envelope. A hypothetical pathway is 
depicted in Figure 7.1. 
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Figure 7.1 Hypothetical gene regulation via 
CRISPR/Cas system in N. meningitidis 8013 
Depicted on the bottom are the CRISPR/Cas locus and 
the rnc locus in N. meningitidis 8013; the loci are drawn 
to scale. The position according to the published 
genome sequence is given in bp beneath the genes. 
Bold arrows indicate genes and their reading direction ; 
loci of non-coding RNAs are indicated by boxes with 
angled arrows. Promotors were predicted by BPROM 
and are depicted as small angled arrows. Vertical lines 
indicate CRISPR spacer. Elements transcribed for 
putative gene regulation are highlighted in grey. Above 
the loci, a gene-regulating function of Cas9 is depicted 
as hypothesized for F. novicida [106]. The tracrRNA, 
scaRNA, and Cas9 build a complex that recognizes the 
mRNA of an unknown bacterial lipoprotein by its 
sequence and degrades it by cleavage. In this way, 
Cas9 may influence the interaction of N. meningitidis 
with human epithelial cells such as Detroit562 in vitro. It 
is shown that RNase III, encoded by rnc, interacts with 
tracrRNA, and thus may also play a role in the gene 
regulation (not depicted) [45]. Adapted from [107] 
 
The most important adhesins are the tfp, Opa, and Opc, 
minor adhesins such as NhhA, App or NadA, and the 
polysaccharide capsule [14, 49, 50]. Each of those 
adhesins is a potential target of Cas9 and thus a 
potential link to the observed phenotype. Further 
experiments based on this study revealed that in strain 
8013, the expression of pilE and the serogroup C 
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capsule did not differ between the mutant strains, the 
wild type, and the complemented strains [108]. Thus, the 
capsule and PilE are unlikely targets of Cas9’s gene-
regulating function. Nevertheless, the function or 
biogenesis of the meningococcal tfp as well as NhhA, 
App and NadA are reasonable candidates. 
Assuming these possible pathways, it has to be 
explained why the knockouts in 8013 and WUE2594 led 
to different results in the adhesion and invasion assay, 
while the comparison of the CRISPR/Cas loci did not 
reveal major differences (Table 6.5).  
As depicted in Figure 3.1, strain 8013 and WUE2594 
obtain tfp of different classes [55]. In addition to that and 
the differing serogroup, the comparison of the adhesion 
associated genes listed in Table 7.2 reveals major 
differences in tfp glycosylation and biogenesis as well as 
notable sequence dissimilarities at the tfp associated 
proteins PilC1 and PilC2, whereas NhhA, App, and 
NadA are present and similar in strain 8013 and 
WUE2594. 
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Table 7.2 Comparison of 8013 and WUE2594 adhesins 
 adhesin 8013 WUE2594 annotation 
 
Capsule 
 (serogroup) 
C A  
Type IV pilus   
 tfp class I II  
  BSNRa  
 
pilE 1.0 0.80 major pilin PilE 
pglA Ψ complete 
pilin glycosyl 
transferase A 
pglB2 complete truncated 
pilin glycosyl 
transferase B2 
pglC 1.0 0.81 
pilin glycosyl 
transferase PglC 
pglD 1.0 0.88 
pilin glycosylation 
protein PglD 
 pglE Ψ complete 
pilin glycosyl 
transferase E 
 pilC1 1.0 0.62 
tfp-associated protein 
PilC1 
 pilC2 1.0 0.68 
tfp-associated protein 
PilC2 
 pilD 1.0 0.95 
type IV prepilin-like 
proteins leader peptide 
processing enzyme PilD 
(prepilin peptidase) 
 pilF 1.0 0.99 
tfp biogenesis protein 
PilF 
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 adhesin 8013 WUE2594 annotation 
 pilG 1.0 0.99 
tfp biogenesis protein 
PilG 
 pilH complete truncated 
tfp biogenesis protein 
PilH 
 pilI 1.0 0.75 
tfp biogenesis protein 
PilI 
 pilJ complete Ψ 
tfp biogenesis protein 
PilJ 
 pilK 1.0 0.90 
tfp biogenesis protein 
PilK 
 pilM 1.0 0.99 
tfp biogenesis protein 
PilM 
 pilN 1.0 1.0 
tfp biogenesis protein 
PilN 
 pilO 1.0 0.98 
tfp biogenesis protein 
PilO 
 pilP 1.0 0.98 
tfp biogenesis 
lipoprotein PilP 
 pilQ 1.0 0.99 tfp secretin PilQ 
 pilS1 1.0 0.48 pilS1 cassette 
 pilS2 1.0 0.48 pilS2 cassette 
 pilS3 1.0 0.55 pilS3 cassette 
 pilS4 1.0 0.60 pilS4 cassette 
 pilS5 1.0 0.89 pilS5 cassette 
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 adhesin 8013 WUE2594 annotation 
 pilT 1.0 0.98 
tfp retraction ATPase 
PilT 
 pilT2 1.0 0.99 PilT-like protein PilT2 
 pilU 1.0 0.98 PilT-like protein PilU 
 pilV 1.0 0.91 minor pilin PilV 
 pilW 1.0 0.99 
tfp biogenesis 
lipoprotein PilW 
 pilX 1.0 0.92 minor pilin PilX 
 pilZ 1.0 0.98 PilZ-like protein 
Outer membrane 
proteins 
status  
 opc missing complete 
outer-membrane protein 
Opc 
 opaA Ψ complete opacity protein A 
 opaB Ψ complete opacity protein B 
 opaC Ψ complete opacity protein C 
 opaD Ψ complete opacity protein D 
Minor adhesins BSNRa  
 nhhA 1.0 0.73 
autotransporter adhesin 
NhhA 
 app 1.0 0.64 autotransporter App 
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 adhesin 8013 WUE2594 annotation 
 nadA 1.0 0.73 
autotransporter adhesin 
NadA 
 
Ψ pseudogene; missing: no similarities in sequence alignment, 
complete: complete sequence for a potentially functional protein  
a Bit Score Normalized Ratio, Bitscore of sequence alignment relative 
to the Bitscores obtained for strain 8013 self-hit (see Table 6.5)  
Since Opc and Opa are absent in 8013, they may be 
precluded as potential Cas9 targets. In addition to the 
findings in Table 7.2, the genes encoding the Opa 
proteins are known to be phase variable [109], and the 
polymeric tracts of all four genes in 8013 are in OFF-
state [108]. Hypothetically, the adhesion and invasion 
assay performed with strain WUE2594 revealed no 
differences between the wild type and the knockout 
strains because the capacity to adhere was likely 
mediated by those outer-membrane proteins. In 8013, 
where those major adhesins are absent, the knockouts 
and the potentially associated alterations in the set of 
adhesin and/or the envelope integrity could have a 
greater influence on cell adhesion. Moreover, their 
absence in N. meningitidis strain 8013 might explain the 
deficiency of invasive behaviour (Chapter 6.3.2).  
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Potentially, the adhesion is influenced in the same way 
as in F. novicida, where blp was downregulated by Cas9 
[35] and thereby the cell envelope’s integrity was 
enhanced, which affects antibiotic resistance [106]. A 
similar mechanism has also been described for C. jejuni, 
where Cas9 was shown to affect virulence by controlling 
the topology and composition of the bacterial cell 
envelope [42]. 
Subsequent to this study, the transcriptomes of the 8013 
wild type strain and the 8013 cas9 knockout strains were 
compared by transcriptome sequencing [108]. While the 
classical adhesins were not differentially expressed, the 
mRNA of a hypothetical blp encoded by NMV_0031 was 
found to be strongly upregulated in the mutant strains. 
Additionally, RNAs bound to Cas9 were identified by 
Cas9 coimmunoprecipitation followed by deep-
sequencing of the gathered RNA [108]. 
Adhesin-encoding RNAs were again not identified but 
the non-coding RNA NMnc0040 was significantly 
enriched. Therefore, these data somehow resemble the 
situation in F. novicida, although the meningococcal blp 
is about 100 AAs shorter and has only 27% similarity to 
its counterpart in F. novicida [108].   
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7.4 Outlook and Conclusion 
The adhesion and invasion assays revealed that cas9, 
rnc, and tracrRNA are required for adhesion to human 
nasopharyngeal cells in N. meningitidis strain 8013 but 
not WUE2594. Since the crossing of the mucosal barrier 
is a crucial step in developing IMD, the CRISPR/Cas 
locus thus contributes to meningococcal virulence in a 
strain-dependant manner.  
This study set the basis for ongoing research by 
revealing a gene regulation pathway using Cas9 that is 
novel in N. meningitidis. It has to be demonstrated how 
exactly Cas9 interacts with its targets. This will 
furthermore deepen the understanding of the function 
and versatility of the CRISPR/Cas system in 
meningococci, a system with wide-ranging applicability 
for research and medicine.  
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9 Annex 
9.1 Abbreviations 
adk adenylate kinase 
Anti-DIG-ATP Anti-Digoxidenin-AP Fab fragments 
App adhesion and penetration protein 
APS ammonium persulfate 
ARM arginine-rich motive 
blp bacterial lipoprotein  
bp base pairs 
BSA bovine serum albumin 
BSNR bit score normalized ratio 
cas CRISPR associated 
CC clonal complex 
CFU colony-forming units 
cnl capsule null locus 
COS plates 
columbia agar plates with 5% sheep 
blood 
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CRISPR 
clustered, regularly interspaced short 
palindromic repeats 
crRNA CRISPR RNA 
CSPD 
chloro-5-substituted adamantly-1,2-
dioxetane phosphate 
CTP carboxy-terminal domain 
ddH2O double distilled water 
DIG digoxygenine 
DNA desoxyribonucleic acid 
dNTPs desoxynucleotide triphosphates 
DTT dithiothreitol 
EDTA ethylendiamin-tetra-acetic acid 
FCS fetal calf serum 
fkbP peptidyl-prolyl cis-trans isomerase 
G4 guanine quartets 
GCB N. gonorrhoea medium base 
GCBL N. gonorrhoea liquid medium 
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gDNA genomic DNA 
HCl hydrogen chloride 
IMD invasive meningococcal disease 
katA catalase 
kb kilo base pairs 
KCl potassium chloride 
kD kilo Dalton 
LB Luria-Bertani medium 
LPS lipopolysaccharides 
lpxC 
UDP-3-O-[3-hydroxymyristoyl] N-
acetylglucosaminedeacetylase 
M molar (mol/litre) 
Mb mega base pairs 
MDA 
meningococcal disease associated 
prophage 
MLST multilocus sequence typing 
MOI multiplicity of infection 
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MOPS 3-(N-morpholino)-propanesulfonic acid 
n.d. no data 
n.s. not significant 
NaCl sodium chloride 
NadA neisserial adhesin A 
NaOH sodium hydroxide 
NCBI 
National Center of Biotechnology 
Information 
Nf neisserial filamentous phage 
NhhA Neisseria hia homolog A 
Nm N. meningitidis 
NTD amino-terminal domain 
Oca oligomeric coiled-coil adhesin 
OD595 optical density measured at 595 nm 
OD600 optical density measured at 600 nm 
Opa Opacity associated proteins 
Opc Opacity proteins 
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PAA polyacrylamide 
PABA 4-Aminobenzoic acid 
PAM pattern adjacent motive 
PBS phosphate-buffered saline 
PBS-T PBS-Tween 
PCR polymerase chain reaction 
pip proline iminopeptidase 
PorA porine A 
PPM proteose peptone medium 
PPM+ 
proteose peptone medium with 
supplements (Table 4.13) 
RNA ribonucleic acid 
rnc RNase III 
rpm rounds per minute 
RT room temperature 
scaRNA small CRISPR/Cas associated RNA 
SDS sodium-dodecyl-sulfate 
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SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SEM standard error of the mean 
serC phosphoserine aminotransferase 
SG serogroup 
SOB super optimal broth 
SOC super optimal broth with glucose 
SSC saline-sodium-citrate buffer 
SSPE saline-sodium-phosphate-EDTA buffer 
ST sequence type 
st. dev. standard deviation 
Ta annealing temperature 
TAE TRIS-acetate-EDTA 
TEMED tetramethylethylenediamine 
tfp type IV pilus 
Tm melting temperature 
tracrRNA trans activating CRISPR RNA 
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TRIS trishydroxymethylaminomethane 
U units 
β-ME beta-mercaptoethanol 
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